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Abstract 
 
Non-alcoholic fatty liver disease (NAFLD) is characterised by the accumulation of fat 
in the liver and is associated with liver-related morbidity and mortality. Nevertheless, 
the leading cause of death in these patients is cardiovascular disease (CVD). Excess 
abdominal visceral adipose tissue (VAT) is frequently expressed in NAFLD and is 
considered a pivotal feature in the pathogenesis of NAFLD which is predictive of CVD. 
Endothelial dysfunction is an early manifestation in the development of atherosclerosis 
and is characterised by a diminished bioavailabilty of the anti-atherogenic molecule NO, 
which is secreted by the endothelium of all blood vessels throughout the vascular tree. 
Limited pharmacological treatment is available to reduce hepatic fat, therefore, lifestyle 
modification interventions comprised of structured exercise and diet are recommended 
as a non-pharmacological management strategy to reduce hepatic fat in NAFLD. The 
primary aim of this thesis was to explore nitric oxide (NO)-mediated endothelial 
function at different levels of the vascular tree in NAFLD patients and to establish 
whether supervised exercise training has a sustained therapeutic impact on endothelial 
function. 
 
Thirty-two NAFLD patients (21 males, 11 females, 48±2yrs, BMI 31±1kg/m2) and 
eighteen matched controls (8 males, 10 females, 48±2yrs,  BMI 30±1kg/m2) underwent 
magnetic resonance imaging (MRI) to quantify abdominal VAT and proton magnetic 
resonance spectroscopy (1H-MRS) to determine intrahepatocellular triglyceride content 
(IHTC). Brachial artery flow mediated dilatation (FMD) (as an index of endothelial NO 
function) was also assessed. IHTC (27.2±3.0 vs. 2.9±0.4%) and abdominal VAT 
(5.4±0.3vs. 3.4±0.2 l) were elevated in NAFLD patients when compared with controls 
(P<0.0005). FMD was significantly impaired in NAFLD patients when compared with 
controls (4.8±0.3 vs. 8.3±0.7%, P<0.0005). A significant inverse correlation was 
observed between FMD and abdominal VAT (r = -0.48, P=0.01) in NAFLD patients, 
but no relationship was observed between FMD and IHTC (P>0.05).  Impairment in 
FMD remained in NAFLD patients following independent covariate adjustment for 
abdominal VAT (5.0±0.5 vs. 7.3±0.7%, P=0.01).  These findings indicate that excess 
IHTC and abdominal VAT do not explain endothelial dysfunction in NAFLD. 
 
Twenty NAFLD patients were randomly assigned to either 16-weeks of supervised 
moderate intensity (30-60% HRR, 30-45 min, 3-5 times per week) exercise training 
(n=13, 50±3yrs, BMI 30±1kg/m2) or to 16-weeks of conventional care lifestyle advice 
(n=7, 47±6yrs, BMI 31±2kg/m2). Supervised exercise training induced a greater 
improvement in FMD when compared with conventional care (3.6±0.6 vs. 0.3±0.8%, 
P=0.004). There was no significant difference between the effect of exercise and 
conventional care on IHTC or abdominal VAT (P>0.05). These data suggest that 
supervised exercise training is an effective management strategy in NAFLD capable of 
improving conduit artery endothelial function independent of IHTC and abdominal 
VAT. 
 
In order to explore the longevity of the exercise-induced improvements in conduit artery 
endothelial function, a 12-month follow up assessment was performed in 9 of the 
NAFLD patients (5 males, 4 females, 50±5yrs, BMI 30±1kg/m2) who completed the 16-
week supervised exercise training intervention. The exercise-induced improvement in 
FMD (5.1±0.8 vs. 7.9±0.8%; P=0.004) was abolished 12 months following the 
cessation of supervised exercise training (7.9±0.8 vs.5.0±0.5%; P=0.02), returning to a 
similar level observed at baseline (5.1±0.8 vs. 5.0±0.5%; P=0.95).These findings 
indicate that in order to chronically sustain exercise-induced improvements in 
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endothelial function in NAFLD patients, long-term exercise supervision and guidance is 
required. 
 
Cutaneous NO-mediated microvessel function reflects generalised microvascular 
function and provides a translational model to investigate pre-clinical disease, but has 
not been previously investigated in NAFLD. NO-mediated vasodilatation in the 
cutaneous microvessels was examined in 13 NAFLD patients (7 males, 6 females, 
50±3yrs, BMI 31±1kg/m2) and 7 matched controls (3 males, 4 females, 48±4yrs, BMI 
30±2 kg/m2).  Microdialysis fibres were embedded into the skin of the forearm and laser 
Doppler probes placed over these sites. Both sites were then heated to 42°C, with saline 
solution infused in one probe and L-NG-monomethyl arginine (L-NMMA) through the 
second. Following baseline assessment, 11 NAFLD patients were randomly assigned to 
16-weeks of supervised moderate intensity exercise training (n=6, 45±5yrs, BMI 
31±1kg/m2) or to 16-weeks of conventional care (n=5, 51±3yrs, BMI 30±21kg/m2). The 
NO contribution to skin blood flow in response to incremental heating was not different 
between NAFLD patients and controls (P=0.47) at baseline.  However, significant 
differences were evident in NO contribution between the exercise training and 
conventional care group (P=0.01), suggesting that supervised exercise training improves 
cutaneous NO-mediated microvascular endothelial function in NAFLD patients.  
 
This thesis suggests that supervised exercise training has a direct therapeutic impact on 
endothelial function in NAFLD which may decrease the risk of future heart disease and 
stroke.  As a cardioprotective management strategy in NAFLD, exercise training is 
superior to that of current conventional care pathways, however, in order to chronically 
sustain the exercise-induced improvements in endothelial function, long term exercise 
supervision and guidance is required.  
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Non-alcoholic fatty liver disease (NAFLD) is characterised by excessive triglyceride 
accumulation within the liver and represents a spectrum of histopathological disorders 
ranging from simple steatosis, to inflammatory non-alcoholic steatohepatitis (NASH) 
with increasing levels of fibrosis and ultimately cirrhosis. Over recent years, NAFLD 
has emerged as the most common form of chronic liver disease in western society, 
affecting approximately 20-30% (Bedogni et al., 2005) of the general population and 
~70-90% of obese and type 2 diabetic individuals (Adams & Angulo, 2005). 
Alarmingly, given the rapid rise of obesity in children globally, NAFLD is now also 
recognized as the most common cause of liver disease in paediatric population 
(Schwimmer et al., 2006).  
 
NAFLD is closely associated with obesity, insulin resistance and type 2 diabetes and is 
now universally regarded as the hepatic manifestation of the metabolic syndrome 
(Marchesini et al., 2001). Like all prediabetic conditions, insulin resistance is an 
integral pathological feature of NAFLD, nevertheless, recent studies indicate that body 
fat distribution also plays an integral role in the pathogenesis of NAFLD (Kelley et al., 
2003; Nguyen-Duy et al., 2003; van der Poorten et al., 2008). Specifically, excess 
abdominal visceral adipose tissue (VAT) seems to be a key determinant of NAFLD, as 
it is potent source of circulatory free fatty acids (FFA) (Eguchi et al., 2006) and is 
closely associated with the severity of NAFLD independently of insulin resistance (van 
der Poorten et al., 2008).  
 
Although NAFLD is primarily a hepatic disorder, cardiovascular disease (CVD) 
accounts for a greater number of deaths than that of liver disease (Ong et al., 2008; 
Soderberg et al., 2010) and some studies report CVD to be the leading cause of 
mortality in NAFLD (Ekstedt et al., 2006; Ong et al., 2008). These findings strongly 
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imply that NAFLD patients are at high risk of atherosclerosis, a progressive disease that 
precedes overt CVD and subsequent cardiovascular events. Importantly, several studies 
have demonstrated that NAFLD confers CVD risk independently of underlying 
metabolic syndrome risk factors such as obesity and hypercholesterolaemia, indicative 
that NAFLD is not merely a marker of CVD but may also be directly involved in its 
pathogenesis (Ruttmann et al., 2005; Targher, 2005b, a; Schindhelm et al., 2007b; 
Targher, 2007; Targher & Arcaro, 2007).   
 
Endothelial dysfunction is the earliest detectable change in the atherosclerotic disease 
process and thus represents a barometer for CVD risk (Vita & Keaney, 2002). 
Endothelial dysfunction is characterised by impaired production of the anti-atherogenic 
molecule nitric oxide (NO), a vital component in the maintenance of efficient 
vasomotor function and the endogenous defence against atherosclerosis. Consequently, 
efficient endothelial function is essential in order to maintain the health of vessels 
throughout the arterial tree. Previous studies have demonstrated that conduit artery 
endothelial dysfunction is present in NAFLD patients (Villanova et al., 2005; Senturk et 
al., 2008); however, the impact of body fat deposition, specifically abdominal VAT, on 
endothelial dysfunction in NAFLD is yet to be investigated. Moreover, cutaneous 
microvessel endothelial function has not been investigated in this high risk group. Given 
that microvascular disease is well documented in associated conditions such as type 2 
diabetes (Fowler, 2008), examination of microvessel endothelial function in NAFLD is 
warranted. 
 
Currently, there is limited pharmacological treatment to reduce hepatic fat, therefore, 
alternative management strategies such as exercise training are recommended as a non-
pharmacological treatment to reduce hepatic fat in NAFLD patients (Bonekamp et al., 
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2008; Johnson et al., 2009; van der Heijden et al., 2010). Nevertheless, no previous 
research study has compared the therapeutic effect of exercise with that of the general 
lifestyle advice (weight loss via increased physical activity and diet) provided as part of 
conventional clinical care. Moreover, the effect of exercise training on conduit artery 
and cutaneous microvessel endothelial function has not been previously investigated in 
NAFLD. 
 
In summary, conduit artery endothelial dysfunction is present in NAFLD, yet the 
mechanisms contributing to this dysfunction are incompletely understood. Excess 
abdominal VAT is highly prevalent in NAFLD and may contribute to endothelial 
dysfunction. NAFLD is a prediabetic condition, and therefore these patients are at high 
risk of microvascular complications that are associated with type 2 diabetes, such as 
neuropathy and retinopathy. Nevertheless, no research studies have been conducted on 
cutaneous microvessel endothelial function in this high risk group. Critically, CVD is 
the leading cause of death in NAFLD, however, the effect of exercise training on 
conduit artery and microvessel endothelial function as a cardio-protective management 
strategy has not been previously investigated. Therefore, the overall aim of this thesis is 
to explore the contributing factors to endothelial dysfunction in NAFLD and investigate 
the potential therapeutic effects of exercise training on endothelial function. The 
specific aims are: 
 
1. To examine the impact of intrahepatocellular triglyceride content (IHTC) and 
abdominal VAT on endothelial function in NAFLD patients compared with 
matched controls.  
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2. To utilise a randomised controlled intervention to compare the therapeutic effect 
of a supervised exercise intervention with conventional clinical care on conduit 
artery endothelial function in NAFLD patients.  
 
3. To examine the long-term effects of supervised exercise training on conduit 
artery endothelial function in NAFLD patients 12 months following the 
cessation of a supervised exercise training intervention. 
 
4. To investigate cutaneous microvessel endothelial function in NAFLD patients 
compared with matched controls; and to utilise a randomised controlled 
intervention to compare the effect of supervised exercise training with 
conventional clinical care on cutaneous microvessel endothelial function in 
NAFLD patients.  
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2.1 Non-Alcoholic Fatty Liver Disease 
The accumulation of triglycerides in the liver, in the absence of excess alcohol intake, 
was first described in the early sixties (Thaler, 1962). Nevertheless, the presence of fatty 
liver in the obese and/or diabetic populations was initially considered an incidental and 
benign pathological finding, with little or no clinical significance. Non-alcoholic fatty 
liver disease (NAFLD) has recently emerged as a disease afflicting our increasingly 
obese society. The condition refers to a spectrum of histopathological changes in the 
liver identical to those seen in alcoholic liver disease, but in individuals who do not 
consume significant amounts of alcohol (<10g daily) (Ludwig et al., 1980; Szczepaniak 
et al., 2005). NAFLD represents a spectrum of disorders which may manifest as simple 
steatosis, non-alcoholic steatohepatitis (NASH) or cirrhosis (Figure 2.1).  NASH is 
characterized by hepatic fat accumulation accompanied by hepatocellular damage, 
inflammation and/or fibrosis and represents a more aggressive form of NAFLD with an 
increased prevalence of cirrhosis and end-stage liver disease. However, the factors that 
influence the rate of transition between the different stages of NAFLD are still unclear. 
Thus, the natural history of the disease remains uncertain. 
 
 
Figure 2.1 The histological spectrum of NAFLD. Upper panels represent the physical 
appearance of the liver and lower panels represent liver biopsy images ranging from a 
healthy liver (A), simple steatosis (B), NASH (C) through to cirrhosis (D). 
 
A D C B 
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2.1.1 Aetiology & Pathogenesis 
Within the healthy human body, the liver plays an integral role in regulating fatty-acid 
and triglyceride metabolism by synthesizing, storing, secreting and oxidizing free fatty 
acids (FFA).  FFA are produced naturally within the liver via de novo lipogenesis 
(synthesis of FFA’s from non-fat precursors), however, dietary lipid intake and lipolysis 
of peripheral adipose tissue generate an external source of plasma FFA’s which are 
subsequently absorbed by the liver. Within hepatocytes, FFA’s either undergo 
esterification to form triglycerides which are stored and ultimately exported in the form 
of very low density lipoproteins (VLDL) or β-oxidation within the mitochondria and 
peroxisomes. Collectively, these mechanisms maintain equilibrium between supply, 
formation, consumption and disposal of FFA. 
 
The exact mechanisms that cause hepatic triglyceride accumulation and subsequent 
hepatocellular damage within NAFLD patients are incompletely understood. As a 
consequence, the current theories alluding to the aetiology and pathogenesis of NAFLD 
remain hypothetical. However, insulin resistance, oxidative stress and an inflammatory 
cascade are believed to play integral roles in the progression of NAFLD. The most 
widely accepted hypothesis explaining the pathophysiology and progression of NAFLD 
is the “two hit theory” proposed by Day and James (1998). In brief, the primary insult 
relates to insulin resistance and the subsequent development of steatosis; the secondary 
insult of increased oxidative stress and the generation of pro-inflammatory cytokines 
(principally tumour necrosis factor; TNF-α) causes an inflammatory reaction, 
steatohepatitis, with eventual progression to fibrosis.  
 
Simple steatosis is a consequence of a disruption to normal hepatocyte lipid 
metabolism. In the insulin resistant state, the inhibitory effect of insulin on peripheral 
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adipose lipolysis is diminished which causes an influx of circulatory plasma FFA and 
subsequently an increase in FFA absorption by the liver. Moreover, hyperinsulinaemia, 
which is commonly associated with insulin resistance, provokes an increase in de novo 
lipogenesis (Browning & Horton, 2004), which further adds to FFA accumulation 
within the hepatocytes. Clearly, high dietary fat intake is also an important factor that 
will add to the overall supply of plasma FFA to the liver. This increased FFA 
availability exceeds the mitochondrial β-oxidation capacity (Browning & Horton, 2004) 
and therefore, in order to dispose of the excess FFA, esterification is up-regulated. 
Nevertheless, in the presence of insulin resistance, synthesis and disposal of VLDL is 
also down regulated (Paschos & Paletas, 2009), causing esterified triglycerides to 
accumulate within the hepatocytes and thus promote steatosis (“first hit”) (Figure 2.2).  
 
 
Figure 2.2 Processes involved in the development of hepatic steatosis. Thick lines 
indicate dominant effect on triglyceride concentration. FFA’s from adipose tissue are 
the dominant source of fatty acids for hepatic triglyceride, followed by de novo 
lipogenesis (DNL) and derived fatty acids from dietary fat. Hepatic triglyceride 
concentration is also a function of hepatic β-oxidation (β-ox) and the synthesis, removal 
and clearance of very low density lipoproteins (VLDL) (Johnson & George, 2010). 
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Over time, increased fat accumulation promotes hepatic insulin resistance as part of 
lipotoxicity, which may exacerbate overall insulin resistance and consequently advance 
the progression of steatosis to NASH. It is still unclear why some patients progress past 
a steatosis stage and develop inflammation and fibrosis. However, factors thought to be 
involved in the progression of steatosis to NASH (“second hit”) include lipid 
metabolism abnormalities, increased hepatic lipid peroxidation, production of reactive 
oxygen species (ROS), activated stellate cells, and abnormal patterns of cytokine 
production (Younossi, 1999; Chitturi & Farrell, 2001). Indeed, when FFA accumulation 
within the hepatocytes exceeds the metabolic capacity of the mitochondria, the rate of 
β-oxidation increases, which results in the formation of ROS and provokes subsequent 
oxidative stress. Excessive ROS formation promotes the release of inflammatory 
cytokines (TNF-α and leptin) and can reduce the availability of anti-inflammatory 
substances such as adiponectin (Nishida et al., 2008). The interplay between 
inflammatory mediators and the activation of stellate cells promotes fibrosis, which in 
turn can reduce hepatocyte regeneration and cause the liver to become cirrhotic. 
 
2.1.2 Diagnosis and Clinical Manifestations 
Most individuals with NAFLD are asymptomatic and show no clinical signs of liver 
disease. Indeed, diagnostic markers such as ultrasound and serum liver enzyme 
abnormalities are often identified unintentionally at routine check-up or when patients 
seek medical consultation regarding a different disease. Nevertheless, some patients 
report fatigue and/or vague right upper quadrant abdominal discomfort, but these 
symptoms are not reported frequently. The diagnosis of NAFLD requires evidence of 
fatty infiltration of the liver in the absence of excessive alcohol consumption. The 
volume of alcohol consumption required to promote hepatic steatosis and steatohepatitis 
is uncertain, but a daily limit of 20g (approximately 2 standard units) is commonly 
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recognised as the threshold. It is imperative that excessive alcohol consumption is 
excluded as possible aetiology as the histological features of NAFLD are 
indistinguishable from alcoholic fatty liver disease (Adams & Angulo, 2005). 
Additionally it is crucial to exclude all other liver related pathologies, as the histological 
manifestations of NAFLD are similar to those observed in secondary causes of chronic 
liver disease, such as viral hepatitis, autoimmune hepatitis, or the use of hepato-toxic 
drugs.  
 
Mild or moderate elevation of serum liver enzymes, usually restricted to alanine 
aminotransaminase (ALT) and aspartate aminotransaminase (AST) (Angulo et al., 
1999; Sorbi et al., 1999; Clark et al., 2003), are the most common and often the only 
laboratory abnormality found in NAFLD patients. However, it has been reported that 
liver enzymes may be within the normal range in up to 78% of NAFLD patients 
(Browning et al., 2004) Indeed, several studies have reported ALT to be an insensitive 
and non-specific marker of NAFLD and therefore an inappropriate diagnostic tool 
(Mofrad et al., 2003; Browning & Horton, 2004; Zelber-Sagi et al., 2006). These 
findings suggest that measurement of serum liver enzyme in isolation cannot be reliably 
used to exclude the presence of steatosis and more advanced forms of NAFLD. 
 
Liver biopsy is considered the gold standard technique used to diagnose NAFLD, 
whereby histological confirmation requires a minimum of 5% steatosis to be present 
relative to the total liver weight (Adams & Angulo, 2005). Currently, liver biopsy is the 
only method capable of differentiating between NASH and steatosis with or without 
inflammation (Bianchi, 2001; Saadeh et al., 2002). Furthermore, liver biopsy allows 
clinicians to exclude other causes of liver disease, estimate prognosis and determine 
progression of fibrosis over time. Importantly, it has been suggested that a liver biopsy 
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is integral in establishing a true reflection of disease progression or response to therapy 
as serum liver enzymes improve over time regardless of whether hepatic fibrosis 
progresses or improves (Adams et al., 2005b). Nevertheless, liver biopsy is an invasive 
procedure that many patients are reluctant to endure as part of their clinical care, and 
incurs a risk of infection, haematoma formation or more significant internal bleeding. 
Together, these factors make the use of liver biopsy ethically difficult in a research 
context and impractical for longitudinal studies. Furthermore, biopsies are subject to 
sampling error, providing quantitative information on only a small isolated volume of 
liver (0.01–0.05 ml), which may be of limited use in the presence of heterogeneous 
intrahepatocellular lipid distribution (lipid accumulation within hepatocytes) (Thomas et 
al., 2005). 
 
In most cases, the clinical diagnosis of NAFLD is made upon persistently elevated liver 
enzyme levels and the presence of an ‘echo-bright’ liver on ultrasound. The sensitivity 
and specificity of ultrasound for detecting >33% steatosis is between 60-94% and 88-
95% respectively, although this accuracy falls with increasing BMI and in cases with 
<33% steatosis (Joy et al., 2003). Furthermore, ultrasonography is highly operator 
dependent and is unable to quantify the degree of steatosis present. In contrast, both 
magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H-
MRS) give a non-invasive and quantitative diagnosis of NAFLD. Indeed, a good 
correlation has been reported between the diagnostic findings of MRI, ultrasound and 
biopsy in NAFLD patients (Fishbein et al., 2005), whereas, findings from 1H-MRS 
correlate closely with ultrasonographic confirmation of steatosis (Lewis & Mohanty, 
2010). 1H-MRS has a higher sensitivity in detecting hepatic fat content in healthy 
people and in the quantitative analysis of steatosis than cross-sectional MRI (Thomas et 
al., 2005; Machann et al., 2006; Guiu et al., 2009). It is likely that 1H-MRS reflects the 
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severity of steatosis with greater accuracy because of its direct measurement of the 
triglyceride content within hepatocytes. Moreover, 1H-MRS is able to implement multi-
voxel (i.e. site) rather than single-voxel measurements of intrahepatocellular lipid, 
allowing for reproducible assessment of the heterogeneous distribution of triglyceride 
present in steatosis (Irwan et al., 2008). Consequently, 1H-MRS is now commonly 
regarded as the non-invasive ‘gold standard’ technique for quantifying hepatic steatosis 
(Cusi, 2009), whereby diagnosis of NAFLD is confirmed upon ≥5.56% hepatic 
triglyceride concentration (Szczepaniak et al., 2005). Nevertheless, both MRI and 1H-
MRS are currently too expensive to be frequently utilised in a clinical setting so are 
currently only implemented as research tools. 
 
2.1.3 Prevalence & Epidemiology 
NAFLD is the most common form of chronic liver disease in western society, affecting 
approximately 20-30% of individuals (Bedogni et al., 2005). The prevalence of NAFLD 
is increasing steadily and is extremely common in obese individuals, type 2 diabetic 
patients and individuals displaying components of the metabolic syndrome with a 
prevalence of ~70-90% (Adams & Angulo, 2005; Marchesini et al., 2005; 
Neuschwander-Tetri, 2005).  The association between NAFLD and obesity is also 
present in the paediatric population, with an overall prevalence of NAFLD in 2.6% of 
children, increasing up to 40% in obese children, and is consequently the leading cause 
of chronic liver disease in childhood (Schwimmer et al., 2006). Although both sexes 
seem to be equally affected by NAFLD (Bedogni et al., 2005), a large multi-ethnic 
population based study reported that the prevalence of NAFLD varies greatly with 
ethnicity (45% in Hispanic, 33% in Whites, 24% in Blacks). Furthermore, Jimba et al. 
(2005) demonstrated a 29% prevalence of NAFLD among healthy Japanese adults. 
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Collectively, these data indicate that NAFLD has reached epidemic proportions in 
different populations around the world.  
 
Numerous studies (Fassio et al., 2004; Adams et al., 2005b; Ekstedt et al., 2006) have 
demonstrated that ~20-30% of patients with NAFLD develop NASH, and 5-8% with 
NASH will progress to cirrhosis (Lee, 1989; Powell, 1990; Cortez-Pinto et al., 2003). 
Alarmingly, it has also been reported that NAFLD accounts for at least 13% of 
hepatocellular carcinoma cases (Marrero et al., 2002).  In contrast, other studies have 
demonstrated that patients with simple steatosis who show no evidence of 
steatohepatitis have a relatively benign liver-related prognosis with 1.5% developing 
cirrhosis and 1% dying from liver-related causes over one or two decades (Teli et al., 
1995; Matteoni et al., 1999; Dam-Larsen et al., 2004). Nevertheless, Matteoni et al. 
(1999) reported an increase of up to 11% in liver-related death among patients with 
biopsy diagnosed NASH. 
 
Importantly, Adams et al. (2005a) conducted a seven year follow up study involving 
420 individuals with NAFLD and compared all-cause mortality rates with those of the 
general population. In this cohort, liver disease was the third leading cause of death 
compared with the thirteenth leading cause in the general population. Interestingly, 
ischaemic heart disease accounted for a greater number of deaths (25%) than liver 
disease (13%) in the NAFLD population. This finding is supported by (Ong et al., 2008) 
who reported cardiovascular disease to be the leading cause of death in a cohort of 80 
NAFLD patients. Taken together, the current evidence indicates that NAFLD patients 
have an increased risk of all-cause mortality compared to the general population (Jepsen 
et al., 2003). But, it is likely that this is only in part due to liver related death with a 
larger proportion due to cardiovascular related mortality.  
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2.2 Metabolic features of NAFLD  
NAFLD patients appear to encompass several co-morbidities, which seem to influence 
the severity of NAFLD as well as increasing the risk of cardiovascular disease (CVD).  
Insulin sensitivity and body fat deposition are key pathogenic factors associated with 
NAFLD, which appear to have an intricate and complex relationship in the disease 
pathogenesis. If the balance between these two factors is disrupted, the risk of hepatic 
steatosis increases, as well as the likelihood of the disease progressing to NASH, 
fibrosis and cirrhosis.  
 
2.2.1 Obesity and body fat deposition 
It is well established that NAFLD is strongly associated with global obesity (Fabbrini et 
al., 2010) and elevated waist circumference (Targher & Arcaro, 2007) with the severity 
of NAFLD likely to increase with the degree of obesity (Wanless & Lentz, 1990). In 
keeping with these findings, numerous studies have reported a reduction in steatosis 
following gradual weight loss (Adams & Angulo, 2005). It appears that body fat 
distribution plays an important role in the pathogenesis of NAFLD, and specifically, 
excess abdominal VAT (adipose tissue stored around the internal organs of the 
abdomen) seems to be a key determinant, due to its strong association with insulin 
resistance and possibly as a source of FFA (Eguchi et al., 2006). Indeed, even in 
NAFLD patients with a healthy weight and BMI, there is a strong association between 
abdominal VAT accumulation and insulin resistance (Chitturi et al., 2002; Park et al., 
2008). Furthermore, abdominal visceral adiposity is positively correlated with steatosis 
(Kelley et al., 2003; Nguyen-Duy et al., 2003) and hepatic insulin resistance (Miyazaki 
et al., 2002), and interestingly, is closely linked with the severity of NAFLD 
independently of insulin resistance (van der Poorten et al., 2008). 
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Although most studies have found abdominal VAT to have a stronger relationship with 
insulin resistance (Cnop et al., 2002; Miyazaki et al., 2002), subcutaneous adipose 
tissue (SAT) is also associated with the development of NAFLD, as it has a greater 
overall mass that VAT and therefore contributes more circulating FFA. Indeed, 59% of 
triglyceride that accumulates in the liver of NAFLD patients is derived from circulating 
FFA’s and the majority of this is from non-splanchnic sources (Donnelly et al., 2005). 
Nevertheless, VAT is metabolically more active than SAT (Montague & O'Rahilly, 
2000) and is therefore more susceptible to lipolysis. VAT and SAT can also act as an 
endocrine source by secreting numerous adipokines such as FFA, adiponectin, leptin, 
and TNF-α into the plasma circulation (Ronti et al., 2006). Once absorbed by the liver, 
these adipokines play a pivotal role in the disruption of hepatocyte lipid metabolism and 
subsequently aid the development of NAFLD. 
 
2.2.2 Insulin resistance  
Insulin resistance can be defined as a condition in which higher than normal insulin 
concentrations are required to achieve normal metabolic responses, or when normal 
insulin concentrations fail to achieve a normal metabolic response. Adipose insulin 
resistance refers to a decreased suppression of lipolysis, whereas, hepatic insulin 
resistance is characterised by impaired glycogenesis and increased glucose production 
(Bugianesi et al., 2005a). It is well established that insulin resistance is associated with 
NAFLD and its severity (Bugianesi et al., 2005b). This relationship was first 
demonstrated by Marchesini et al. (1999), who observed an independent correlation 
between insulin resistance, evaluated by HOMA-IR (fasting glucose x fasting insulin / 
22.5), and ultrasonographic NAFLD in non-diabetic patients. Since then, this 
relationship has been confirmed in biopsy proven NAFLD cohorts using the 
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euglycaemic clamp as a more robust method of assessing insulin resistance (Marchesini 
et al., 2001; Sanyal, 2001).  
 
Much like peripheral insulin resistance, NAFLD is also associated with adipose insulin 
resistance (Marchesini et al., 2001), which promotes an upregulation in FFA secretion 
by adipocytes. Similarly, NAFLD patients also exhibit hepatic insulin resistance 
(Seppala-Lindroos et al., 2002; Bugianesi et al., 2005a), whereby the suppression of 
endogenous production of glucose is impaired. Indeed, it seems that insulin resistance 
not only provokes hepatic triglyceride accumulation via an increased supply of FFA to 
the liver, but also via hyperinsulinaemia-induced upregulation in hepatic de novo 
lipogenesis. Importantly, it appears that insulin resistance is also involved in the 
progression of steatosis to NASH as several clinical trials have demonstrated that 
insulin resistance is strongly correlated with the severity of fibrosis (Bugianesi et al., 
2005b). The current body of evidence suggests that insulin resistance is the key 
pathophysiological hallmark of NAFLD, promoting both hepatic fat accumulation and 
the progression to NASH. Alarmingly, excess hepatic fat accumulation can also 
exacerbate peripheral insulin resistance, via enhanced basal insulin secretion and 
decreased suppression of hepatic glucose output, and thus generate a vicious circle that 
can ultimately lead to diabetes (Taylor, 2008). 
 
2.3 Type 2 diabetes and the metabolic syndrome 
The association between obesity, insulin resistance, type 2 diabetes and the metabolic 
syndrome is now universally accepted, with NAFLD being increasingly recognised as 
the hepatic manifestation of the metabolic syndrome (Marchesini et al., 2001). The term 
“metabolic syndrome” refers to a clustering of risk factors, including CVD risk factors, 
whose underlying pathophysiology is thought to be related to insulin resistance (Kahn et 
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al., 2005). An individual defined as having the metabolic syndrome exhibits abdominal 
obesity (waist circumference >102cm in men, >88cm in women) plus any two of the 
following factors; elevated triglycerides (≥150 mg/dL), reduced HDL cholesterol (<40 
males, <50mg/dL females), raised blood pressure (systolic >130, diastolic >85mmHg) 
and raised fasting glucose (≥100 mg/dL) (Alberti, 2006). The pathogenesis of NAFLD 
and metabolic syndrome seem to share a common pathophysiological pathway, with 
insulin resistance and hyperinsulinaemia playing a central role (Paschos & Paletas, 
2009). Nevertheless, the exact mechanisms underlying the development of NAFLD are 
not completely understood (see 2.1.1 Aetiology & Pathogenesis). 
 
Over 90% of patients with NAFLD demonstrate at least one feature of the metabolic 
syndrome, with approximately one-third having the complete syndrome (Marchesini et 
al., 2003). Indeed, the prevalence of NAFLD has been consistently associated with 
obesity (60-95%), type 2 diabetes (~70%) and dyslipidaemia (30-90%), which are 
frequently expressed as components of the metabolic syndrome (Bugianesi et al., 
2005b; Cusi, 2009). Kotronen and Yki-Jarvinen (2008) utilised 1H-MRS to elegantly 
demonstrate that all components of the metabolic syndrome correlate with hepatic fat, 
even after adjusting for BMI. Furthermore, with the addition of each of the components 
of metabolic syndrome the risk of steatosis increases exponentially (Marceau et al., 
1999). The metabolic syndrome in NAFLD also increases the likelihood of more severe 
forms of the disease, conferring an odds ratio of 3.2 for the presence of NASH and 3.5 
for the onset of advanced fibrosis (Marchesini et al., 2003). 
 
In light of the pathogenic relationship between insulin resistance and triglyceride 
accumulation within the liver, it is not surprising that NAFLD is highly prevalent in 
type 2 diabetes. Compared with non-diabetic individuals, type 2 diabetic patients are at 
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greater risk of developing NAFLD, fibrosis and cirrhosis (Angulo, 2002; Day, 2006). 
Indeed, a study by Kotronen & Yki-Jarvinen (2008), which utilized H1 MRS to 
determine hepatic fat content, reported that type 2 diabetic patients exhibit 80% more 
hepatic fat than age, weight and sex matched non-diabetic individuals. Importantly, a 
study with a cohort of 458 biopsy-proven NASH patients, reported that type 2 diabetes 
was the single most important predictor of NASH and fibrosis (Fracanzani et al., 2008b). 
Conversely, NAFLD may also be an important early marker of type 2 diabetes, as 75% 
of prospective epidemiological studies have shown that elevated serum liver enzyme 
concentrations predict type 2 diabetes independent of obesity (Kotronen & Yki-Jarvinen, 
2008). Nevertheless, considering that up to 40% of adults with NAFLD progress to 
NASH (Cusi, 2009) and that the majority of patients with cirrhosis are diabetic (Ekstedt 
et al., 2006), it would seem that NASH in type 2 diabetes must be frequently left 
undiagnosed until end-stage liver disease develops. Consequently, greater surveillance 
and more intense screening of NAFLD in individuals at high risk of type 2 diabetes is 
required in order to diagnose this important pre-diabetic condition in its infancy. 
 
2.4 NAFLD and Cardiovascular Disease Risk 
As a consequence of the strong association NAFLD has with metabolic syndrome, as 
well as the mortality statistics for NAFLD patients, much attention has been drawn to 
the possible role of NAFLD in the development of CVD (Figure 2.3). Although, not a 
unanimous finding, most epidemiological studies have revealed that CVD accounts for 
a greater number of deaths than that of liver disease in NAFLD patients (Adams et al., 
2005a; Ong et al., 2008; Soderberg et al., 2010) and some report CVD to be the leading 
cause of mortality (Ekstedt et al., 2006; Ong et al., 2008). These findings strongly imply 
that NAFLD patients are at high risk of cardiovascular events. Indeed, the Hoorn Study 
reported that in 1439 individuals, elevated serum ALT at baseline increased the 10-year 
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risk of coronary heart disease events even after adjusting for components of the 
metabolic syndrome and other CVD risk factors (glucose tolerance status, HbA1c, 
systolic blood pressure, low density lipoprotien cholesterol, BMI) (Schindhelm et al., 
2007a). Supportive epidemiological findings were later reported by Ong et al. (2008), 
who demonstrated that in 80 NAFLD patients (diagnosis confirmed via elevated serum 
liver enzymes); cardiovascular disease accounted for 25% of mortality, whereas, liver-
related disease accounted for only 6% of deaths. 
 
Figure 2.3 Schematic demonstrating potential mechanisms linking NAFLD with CVD 
(Scorletti et al., 2011). 
 
The association between NAFLD and cardiovascular related death has also been 
reported using more robust diagnostic techniques. A Swedish prospective study 
performed a ~28 year follow up in 256 individuals who had previously undergone liver 
biopsy and used the national death registry to obtain mortality data. Up to 118 
individuals were diagnosed with NAFLD, of those, 67 were classified as steatosis and 
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51 as NASH. During the follow-up period 40% of the NAFLD cohort died and 
importantly, CVD was the leading cause of death for the entire NAFLD cohort (30%), 
as well as those exhibiting steatosis alone. CVD was a prominent cause of death in the 
NASH cohort second only to extrahepatic malignancy (Soderberg et al., 2010). This 
data is corroborated by Ekstedt et al. (2006), who followed 129 biopsy-proven NAFLD 
patients for 13.7 years and reported that mortality from cardiovascular and liver related 
causes were significantly increased compared with matched controls and that CVD was 
a far more prominent cause of death than liver-related disease (16% vs. 3%). 
 
Although the above studies provide an insight into the CVD related risk and mortality in 
NAFLD, there is currently paucity in epidemiological studies of this nature, due to the 
recent emergence of NAFLD as a risk factor for CVD. Consequently, clinical surrogate 
markers of CVD, such as intima media thickness (IMT) have been utilised to evaluate 
the CVD risk in NAFLD patients. Recent cross-sectional studies have demonstrated that 
NAFLD patients have a significantly greater carotid artery IMT than matched healthy 
controls (Targher et al., 2004; Brea et al., 2005; Targher et al., 2006; Fracanzani et al., 
2008a). This finding is endorsed by the results of population (Volzke et al., 2005) and 
meta-analysis (Sookoian & Pirola, 2008) based studies demonstrating increased carotid 
IMT and higher prevalence of carotid plaques in NAFLD patients.   
 
Increased CVD risk could be due to the strong clinical association of NAFLD with 
features of metabolic syndrome, as it is known to confer an adverse CVD risk profile. 
However, it is plausible that NAFLD may also act as an independent CVD risk factor in 
addition to the underlying metabolic syndrome risk factors. Indeed, previous research 
(Targher, 2005b; Targher & Arcaro, 2007) has not only demonstrated carotid IMT to be 
significantly higher in individuals with NASH than in those with simple steatosis 
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(0.96±0.15 vs. 1.26±0.24) but, more importantly, that the histological severity of 
NAFLD (i.e., steatosis, necroinflammation and fibrosis) predicted carotid IMT 
independently of classical risk factors, insulin resistance and the metabolic syndrome. 
Moreover, population-based studies have demonstrated an independent association 
between serum liver enzymes and CVD risk (Schindhelm et al., 2007a) and mortality 
(Ruttmann et al., 2005). Consequently, it is hypothesised that NAFLD is not merely a 
marker of CVD but may also be involved in its pathogenesis (Targher, 2007).   
 
2.5 The Role of the Vascular Endothelium in Cardiovascular Risk 
The arterial tree consists of a complex network of blood vessels branching from the 
heart to large conduit arteries, arterioles and capillaries (microvessels). The contractility 
of conduit artery walls allows them to actively vasoconstrict and vasodilate, primarily 
under the control of the sympathetic division of the autonomic nervous system. These 
vessels are characterised by a thick tunica media that contains a greater amount of 
smooth muscle cells compared to other branches of the arterial tree (Figure 2.4). 
Arterioles have much smaller internal diameters than conduit vessels, which change in 
response to either sympathetic or endocrine stimulation. Arterioles branch out from 
conduit vessels and extend to the microcirculation. The capillaries, or microvessels, that 
constitute the microvasculature measure 5-10μm in diameter. Microvessels form an 
interconnected network, or capillary bed, containing direct connections between 
arterioles and venules. Microvessels represent the only component of the arterial tree 
which permit the diffusion of water, small solutes and lipid-soluble substances into the 
surrounding interstitial fluid. A squamous epithelial layer lines the inner surface of all 
blood vessels and is otherwise known as the endothelium (Figure 2.4). 
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Figure 2.4 The arterial tree from the macrovessels through to microvessels. 
 
Atherosclerosis is a progressive disease that precedes overt CVD. It is characterised by 
vascular inflammation and infiltration of lipids, cholesterol, calcium and cellular debris 
into the sub-intima of the arterial wall; resulting in plaque formation, vascular 
remodelling, acute and chronic luminal obstruction and blood flow abnormalities (Stary 
et al., 1995). Clinical manifestations of CVD (e.g. myocardial infarction, angina and 
stroke) become apparent with age and evidence of risk factors, but, the atherosclerotic 
disease process precedes both evidence of risk factors and clinical outcomes (Chan et 
al., 2003). 
 
Endothelial dysfunction is the earliest detectable change in the atherosclerotic disease 
process and thus represents a barometer for CVD risk (Vita & Keaney, 2002). The 
vascular endothelium is a confluent, cellular monolayer that lines the entire vascular 
Arteriole 
 Conduit Artery 
Microvessel 
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compartment at the interface between blood and the vessel wall. Crucially, a healthy 
endothelium mediates anti-atherogenic properties that protect against vasoconstriction, 
smooth muscle cell growth and inflammatory responses (Davignon & Ganz, 2004). In 
the presence of endothelial dysfunction, the endothelium may adopt a phenotype that 
promotes inflammation, thrombosis, vasoconstriction and atherosclerotic lesion 
formation.  
 
A healthy endothelium produces numerous paracrine substances, including nitric oxide 
(NO), which help maintain the health of the vascular wall and regulate vasomotor 
function (Green et al., 2004a). NO is a labile, lipid soluble gas synthesised in 
endothelial cells from the amino acid L-arginine through the action of endothelial nitric 
oxide synthase (eNOS) (Palmer et al., 1988). It rapidly diffuses into the vascular 
smooth muscle of the tunica media where it binds to the enzyme guanylate cyclase 
(Ignarro et al., 1986), resulting in an increase in cyclic guanosine monophosphate, 
which induces smooth muscle relaxation and subsequent vasodilation (Furchgott & 
Jothianandan, 1991) (Figure 2.5).  
 
 
Figure 2.5 Nitric oxide (NO) mediated endothelium-dependent vasodilation (Green, 
2009). 
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Additionally, by releasing NO, the endothelium inhibits platelet and leukocyte 
activation, inflammation and thrombosis while maintaining the vascular smooth muscle 
in a non-proliferative state. Collectively, these biological actions make NO a vital 
component in the endogenous defence against atherosclerosis. Efficient endothelial 
function is therefore essential in order to maintain the health of vessel walls throughout 
the arterial tree.   
 
NO is tonically released by the endothelium at rest and contributes approximately 50% 
to basal vascular tone (Vallance et al., 1989). Production of NO can be up-regulated via 
physiological stimuli such as increased flow and consequent shear stress, or 
pharmacologically utilising receptor agonists such as acetylcholine (ACh), to cause 
acute arterial vasodilation. Vasodilation is a physiological response to an acute release 
of NO during periods of increased flow (Hutcheson & Griffith, 1991). Although the 
preset signalling cascade linking mechanical stimulation to the secretion of NO remains 
incompletely understood, several mechanisms are thought to be involved. For example, 
increased flow and arterial shear stress have been reported to induce endothelial 
potassium channel activation (Oleson & Johnson, 1988), calcium influx in endothelial 
cells (Dull & Davies, 1991) and phosphorylation of serine residue (Groves et al., 1995); 
all of which are thought to play a role in increasing bioavailability of NO. Nevertheless, 
it is important to note that other vasoactive substances can be released by the 
endothelium in response to shear stress, such as prostacyclin and endothelium-derived 
hyperpolarizing factor (Grabowski et al., 1985; Kuchan & Frangos, 1993). NO readily 
reacts with free radicals, and increased oxygen degradation resulting in a reduced 
bioavailability of NO is considered a central feature of endothelial dysfunction. Thus, 
NO bioavailability is commonly utilised as a surrogate marker of endothelial function. 
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2.6 Measurement of Conduit Artery Endothelial Function  
Non-invasive assessment of endothelial function in vivo is commonly utilised to assess 
NO-mediated vasodilator function. In the 1990’s, high-frequency ultrasonographic 
imaging of the brachial artery was developed to assess endothelial function, using a 
technique called flow-mediated dilation (FMD). This method involves direct assessment 
of conduit artery dilator responses to reactive hyperaemia induced by a brief period of 
limb ischaemia (Green et al., 2004a). This stimulus causes a shear stress that provokes 
the endothelium to release NO, which induces a subsequent vasodilation (i.e. increase in 
arterial diameter) that can be imaged using duplex ultrasonography (Dijkhorst-Oei et 
al., 1999). On the assumption that the occluding cuff, which induces the ischaemia, is 
positioned distal to the artery (Doshi et al., 2001) and that the period of ischaemia is not 
greater than five minutes (Mullen et al., 2001), the arterial vasodilator response to this 
stimulus is largely mediated by NO (Joannides et al., 1995; Doshi et al., 2001). Thus, 
FMD provides an index of conduit artery endothelium-dependent NO function (Ganz & 
Vita, 2003). 
 
FMD was first described by Schretzenmayr (1933), however, it was not until 1986 that 
the importance of the endothelium in mediating this response was demonstrated (Pohl et 
al., 1986). Pohl and colleagues (1986) elegantly demonstrated that the femoral artery 
FMD response of canines is significantly attenuated if the endothelium is denuded. 
Soon after, Sinoway et al. (1989) first described the phenomenon of FMD in-vivo 
within humans, reporting a delayed dilation of the brachial artery after the time of peak 
blood flow, following a reactive hyperaemic challenge. Following this, Celermajer et al. 
(1992) demonstrated that an impaired FMD response is exhibited in populations with 
CVD risk factors. Importantly, endothelium-derived NO was confirmed as the primary 
mediator of FMD in humans by Joannides et al. (1995), who reported an attenuated 
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FMD response in the radial artery during the infusion of NO blocker; L-NG-
monomethyl Arginine (L-NMMA). This finding has also been demonstrated in the 
brachial (Doshi et al., 2001; Mullen et al., 2001) and femoral artery (Kooijman et al., 
2008).  
 
Doshi et al. (2001) highlighted the importance of correct cuff placement during the 
FMD technique so to ensure a NO-mediated vasodilator response. This study elegantly 
demonstrated that NO blockade almost completely abolished the vasodilator response to 
FMD when the cuff was placed distal to the imaged site. Distinct from this was the 
observation that when the cuff was positioned proximally, NO blockade had much less 
of an effect on the vasodilator response. Similarly, the duration of the hyperaemic 
stimulus is also an important factor in the validity of FMD. Indeed, Mullen et al. (2001) 
reported that the FMD response to transient reactive hyperaemia (5 minutes) was almost 
completely abolished by NO blockade, however, following a period of sustained 
reactive hyperaemia (>5 minutes) the subsequent FMD response was unaffected by NO 
blockade. Accordingly, in order to produce a vasomotor response that is reflective of 
NO bioavailability, FMD must adhere to stringent guidelines, with any deviation in 
protocol potentially increasing the contribution of alternative vasodilator pathways 
(Green et al., 2005). 
 
2.7 Prognostic Relevance of FMD 
The concept that FMD provides a direct assessment of arterial wall function, rather than 
measurement of the risk factors that impact upon it, has stimulated interest in the 
prognostic value of the technique. Indeed, recent evidence suggests that FMD may 
possess prognostic value in patients at high risk of CVD (Green et al., 2011a) and 
specifically, FMD has been reported to be an accurate independent predictor of occult 
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coronary artery disease (Mutlu et al., 2011). Moreover, the independent prognostic 
information provided by FMD may exceed that of traditional risk factors in clinical 
populations (Naghavi et al., 2003a; Naghavi et al., 2003b). Takase et al. (1998), 
induced endothelium dependent vasodilation in both the coronary and brachial arteries 
as a result of increased flow and subsequent shear stress. This group reported a robust 
relationship between coronary and brachial artery endothelial function and postulated 
that brachial artery FMD could be employed as a prognostic marker of coronary artery 
endothelial function. As well as being strongly and independently associated with CVD 
risk and mortality in coronary artery disease (Takase et al., 1998; Chan et al., 2003); 
FMD has also been reported as an accurate prognostic tool in CVD (Gokce et al., 2003), 
peripheral vascular disease (Brevetti et al., 2003; Gokce et al., 2003) and chronic heart 
failure (Meyer et al., 2005). Such studies suggest that impaired FMD response in 
clinical groups is potentially indicative of cardiovascular endpoints. 
 
Interestingly, several studies have yielded conflicting results regarding the prognostic 
value of FMD in asymptomatic individuals; some of which support the independent 
prognostic value of the technique (Shechter et al., 2009) while others imply no 
difference in the predictive competence of FMD compared with traditional risk factor 
assessment (Shimbo et al., 2007). A noteworthy study by Yeboah and colleagues (2007) 
examined the prognostic value of FMD in asymptomatic older (72-98 years) 
participants and found FMD to be an accurate independent predictor of cardiovascular 
event rate. However, the prognostic value of FMD observed in this study did not 
outweigh that of traditional cardiovascular risk factors. This finding is in agreement 
with previous research works suggesting that FMD may be a less accurate predictor of 
CVD risk in aged cohorts (Witte et al., 2005). A more recent large multi-ethnic 
population based study in 3026 younger asymptomatic participants by the same research 
29 
 
group also reported that FMD was an accurate independent predictor of incident 
cardiovascular events (Yeboah et al., 2009). Importantly, this inverse association 
remained following adjustment for several major CVD risk factors, including the 
Framingham risk score, indicative that the prognostic value of FMD is also apparent in 
individuals with no overt evidence of CVD. 
 
FMD is traditionally considered as an index of NO-mediated vasodilator function and 
thus a marker of NO-bioavailability, although protocols utilised to induce an FMD 
response in humans are not all equally NO dependent (Corretti et al., 2002; Green et al., 
2005). Nevertheless, a recent meta-analysis conducted by Green et al. (2011a) revealed 
that the FMD response to proximal cuff occlusion, which is thought to be less NO-
mediated than the response to distal cuff occlusion (Doshi et al., 2001), is equally 
predictive of future cardiovascular events. Whilst this does not diminish the predictive 
power of FMD, these data suggest that NO may not be the sole contributor to the 
prognostic value of the technique.  
 
2.8 Measurement of Cutaneous Microvessel Endothelial Function 
As outlined above, the assessment of endothelial dysfunction as a surrogate marker of 
CVD has focussed on large conduit arteries. Nevertheless, in recent years a growing 
body of evidence has emerged suggesting that the microcirculation (network of small 
arteries, including cutaneous vessels) may be the initial site of endothelial damage in 
subjects at risk of CVD (Brodsky et al., 2004). Systemic microvascular endothelial 
dysfunction is a key component in the inherent pathogenic complications associated 
with diseases such as type 2 diabetes, hypertension, coronary artery disease and 
hypercholesterolaemia (Joannides et al., 2006). For example, there is a high prevalence 
of microvascular complications among type 2 diabetic patients, including neuropathy 
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and retinopathy. Therefore, it is imperative to independently assess the health and 
function of the microvasculature in clinical populations such as NAFLD. The cutaneous 
circulation has emerged as an accessible and representative vascular bed for 
investigating microvascular endothelial function and disease status. Moreover, 
cutaneous vasodilator endothelial function may reflect generalised microvascular 
function and provide a useful translational model to investigate preclinical 
microvascular disease (Holowatz & Kenney, 2007). 
 
In the past, the efficacy of the cutaneous microcirculation has been assessed using 
techniques such as strain-gauge plethysmography to measure vasodilator capacity 
following various challenges that provoke a maximal dilator response. However, these 
techniques only offer a gross measure of whole limb blood flow and, under controlled 
conditions, only provide an indirect assessment of the skin blood flow (SKBF). 
Consequently, these techniques have been superseded by the application of non-
invasive laser Doppler flowmetry (LDF). This versatile technique allows for more direct 
monitoring of relative blood flow changes both at rest and during maximal provocation. 
As well as providing an index of maximal dilator capacity of the skin (which is 
diminished with age and certain pathology, see; 2.10. NAFLD and Cutaneous 
Microvessel Function), LDF can also be used in conjunction with techniques such as 
iontophoresis and microdialysis to comprehensively interrogate the control of cutaneous 
microvascular endothelial function, by infusing vasoactive agonist and antagonist 
substances.   
 
2.8.1 Intradermal Microdialysis 
Intradermal microdialysis is a technique that allows the continuous local delivery of 
potent pharmacological agents into the epidermis (Figure 2.6) via a semi-permeable 
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membrane, whilst preventing systemic effects.  Flux over this localized area of skin can 
be measured using LDF, therefore, any pharmacological action that evokes a change in 
cutaneous blood flow can be recorded (For details on intradermal microdialysis 
methodology, see General Methodology, Chapter 3). Unlike iontophoresis, which uses 
opposing electrical currents to deliver charged pharmacological agents to localised areas 
of skin, microdialysis does not exhibit any confounding effects of electrical current-
induced hyperaemia. Nevertheless, the technique is limited by the potential confounding 
effect of the trauma caused by fibre insertion. Indeed, cutaneous drug delivery can be 
influenced by probe insertion depth, differences in barrier functions of the skin, lag time 
(duration of time before the substance enters the skin from time of administration), 
elimination or metabolism rate of the delivered agent and possibly the volume of 
distribution (Kreilgaard, 2002). Variability can be minimised through good working 
practice, careful instrumentation and the use of within subject experimental designs, 
whereby the same researcher performs all cannulations; ensuring a consistent 
cannulation depth is maintained across all time points. 
 
 
Figure 2.6 A cross sectional diagram of the skin and integrated microvessels. 
 
32 
 
2.8.2 Heat Stimulation 
Particular interest has grown in the NO-mediated endothelial vasodilator function of 
cutaneous microvessels which has routinely been assessed using thermal provocation 
challenges. Studies have consistently shown NO to be a mediator of cutaneous 
vasodilator responses to both physiological (e.g. heating) and pharmacological stimuli 
(Kellogg et al., 1998; Shastry et al., 1998; Kellogg et al., 1999; Shastry et al., 2000; 
Minson et al., 2001; Shibasaki et al., 2002; Holowatz et al., 2003; Kellogg et al., 2005; 
Stewart et al., 2007). Localised heating at 42°C has been reported to elicit the greatest 
contribution of NO to the vasodilator response (~70%, (Kellogg et al., 1999; Minson et 
al., 2001)), compared to other stimuli such as ACh (~30-60%, (Boutsiouki et al., 2004; 
Kellogg et al., 2005; Stewart et al., 2007)) and whole body heating (~30-40%, (Shastry 
et al., 1998; Wilkins et al., 2003)). It is therefore the most specific methodology 
currently available for investigation of NO-mediated cutaneous vasodilatation. 
 
Localised heating of the skin stimulates a temperature-dependent sustained increase in 
SKBF (Charkoudian, 2003), whereby maximal vasodilation of cutaneous microvessels 
is reached between 42°C and 44°C (Christen et al., 2004). The application of a rapid 
heating protocol (0.5°C increase in heater temperature every 5 seconds) has been 
demonstrated to elicit a biphasic response (Minson et al., 2001) (Figure 2.7). This 
maximal thermo-vasodilator response consists of an initial rapid peak in blood flow 
within the first 10 minutes, followed by a secondary rise to a sustained plateau after 
approximately 20-30 minutes of heating (Minson, 2010). It has been proposed that the 
initial rapid peak is primarily mediated by the axon-reflex of sensory nerves, which 
stimulates the release of known vasodilators; calcitonin gene related peptide and 
substance P which elicit an increase in SKBF. Conversely, the secondary slow rise and 
plateau phase of the localised heating response is reported to be largely NO-mediated 
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(Kellogg et al., 1998; Minson et al., 2001), with recent evidence suggesting that NO is 
generated from the endothelial NO synthase isoform (eNOS) (Kellogg et al., 2008). 
However, eNOS inhibition by intradermal infusion of L-NMMA does not fully suppress 
the plateau phase response to localized heating, suggesting that other vasodilators may 
be involved (Minson, 2010). 
 
 
Figure 2.7 A The local heater temperature of 42°C warms the skin to ~40°C which has 
been shown to elicit maximal cutaneous vasodilatation. B Typical bi-phasic response to 
the application of local heating, with the initial axon reflex stimulating a response ~75% 
of the maximal response, and the secondary plateau phase (NO-dependent) ~87% of 
maximal response (Minson et al., 2001). 
 
To more thoroughly assay the cutaneous NO dilator system, a more gradual heating 
protocol (e.g. 0.5°C rise every 5 minutes) can be utilised that does not provoke the 
initial axon reflex mediated response (~30-40% of maximal response) (Figure 2.8; 
(Black et al., 2009). Consequently, in recent years several studies have adopted this 
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gradual heating protocol to provide a more accurate assessment of cutaneous 
microvessel NO vasodilator function; (Houghton et al., 2006; Black et al., 2008b) and 
complimented this with infusion of Sodium Nitroprusside (SNP), a potent NO donor, 
following either peak thermal or ACh induced hyperaemia, (or a combination) to 
confirm the attainment of maximal cutaneous vascular conductance (Figure 2.8).  
 
 
Figure 2.8 A more gradual applied heating protocol avoids provocation of the initial 
axon reflex mediated response (red trace). Peak thermal-induced hyperaemia can be 
complimented with infusion of SNP to confirm the attainment of maximal cutaneous 
vascular conductance (Black et al., 2008b). 
 
2.9 NAFLD and Conduit Artery Function 
Evidence is beginning to accumulate indicating that NAFLD patients exhibit endothelial 
dysfunction. An elegant study by Villanova et al. (2005) reported a marked decrease in 
FMD in patients with NAFLD, compared to matched healthy controls. Moreover, the 
study also illustrated that NASH patients’ exhibit more pronounced endothelial 
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impairment than patients with isolated simple steatosis. Indeed, the severity of liver 
histopathology among NAFLD patients correlated with level of endothelial impairment, 
independent of BMI, HOMA-insulin resistance and other classic metabolic syndrome 
risk factors. A strength of the aforementioned study was the utilisation of liver biopsies 
to provide a histological diagnosis of NAFLD, which enabled the authors to investigate 
the independent effects of simple steatosis and NASH on endothelial function. 
Nevertheless, Villanova et al. (2005) did not quantify intra-abdominal fat deposition, 
specifically abdominal visceral fat, which is known to be an important mediator of 
NAFLD and independently promote endothelial dysfunction (Romero-Corral et al., 
2010). Senturk et al. (2008) assessed endothelium-dependent and independent 
vasodilatation in 17 individuals with simple steatosis, 15 individuals with NASH and 16 
matched healthy controls. Endothelium-dependent dilatation and endothelium-
independent dilatation were significantly lower in NASH patients compared to those 
with simple steatosis alone.  Furthermore, contrary to previous findings, this study also 
reported that individuals with isolated simple steatoisis do not exhibit endothelial 
dysfunction when compared with matched healthy controls.  
 
It is well established that type 2 diabetic patients demonstrate endothelial impairment 
(McVeigh et al., 1992; Williams et al., 1996; Maiorana et al., 2001). Nevertheless, there 
are only two studies to date that investigate the impact of NAFLD on endothelial 
dysfunction in type 2 diabetes. Kawashima et al. (2009) investigated the degree of 
endothelial dysfunction and insulin resistance in 25 type 2 diabetic patients, 10 of whom 
had biopsy-proven NASH. The study reported that patients with NASH demonstrated a 
significant increase in insulin resistance and a significant decrease in FMD compared to 
those without NASH. However, the severity of inflammation and fibrosis had no 
influence on FMD in type 2 diabetic subjects with NASH. Similarly, Schindhelm et al. 
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(2005) reported that in metabolically well-controlled type 2 diabetic patients, mildly 
elevated ALT levels, as a surrogate marker of NAFLD, were related to an attenuated 
endothelium-dependent dilatation, endothelium-independent dilatation and impaired 
peripheral insulin sensitivity. Thus, taken together it could be hypothesised that the 
presence of NAFLD, and in particular NASH, amplifies the degree of both insulin 
resistance and endothelial dysfunction in type 2 diabetic patients. 
 
2.10 NAFLD and Cutaneous Microvessel Function 
Despite it being well established that NAFLD confers an impaired hepatic 
microcirculatory profile (Ijaz et al., 2003), no previous research has investigated the 
effect of NAFLD on cutaneous microvascular function as a marker of CVD risk. 
Previous studies have shown endothelium derived NO-mediated vasodilator function in 
cutaneous microvessels is related to age (Black et al., 2009) and fitness (Lenasi & 
Strucl, 2004; Black et al., 2009) in healthy individuals. Additionally, a small number of 
studies have investigated the impact of cardiovascular risk factors associated with 
NAFLD on cutaneous microvascular function. For example, Khan et al. (1999) 
demonstrated that individuals with hypercholesterolemia exhibit a diminished SKBF 
response following iontophoresis of ACh and SNP compared with matched controls. 
This finding indicates that both endothelium-dependent and -independent cutaneous 
microvessel vasodilator function is impaired in hypercholesterolaemic patients. 
Similarly, it has also been reported that obese individuals (de Jongh et al., 2004) and 
those at increased risk of coronary heart disease (Klonizakis et al., 2009) exhibit an 
attenuated NO-mediated response to iontophoretically applied ACh; indicative of NO-
mediated microvascular dysfunction.  Although these studies clearly demonstrate that 
individuals with cardiovascular risk factors are at high risk of cutaneous microvessel 
dysfunction, the administration of ACh only elicits ~30-60% of the NO contribution to 
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maximal SKBF (Boutsiouki et al., 2004; Kellogg et al., 2005; Stewart et al., 2007). 
Consequently, information is currently lacking on the exact contribution of NO to the 
microvascular endothelial dysfunction exhibited by patients with cardiovascular risk 
factors. This is of particular relevance to the NAFLD population, as cardiovascular risk 
factors such as hypercholesterolemia and obesity are frequently expressed in this high 
risk group. However, such information can only be elucidated using the intradermal 
microdialysis technique which allows infusion of a specific NO blocker. 
 
Currently, the impact of type 2 diabetes on the cutaneous microvasculature is 
incompletely understood. Some (Caballero et al., 1999; Wick et al., 2006), but not all 
(Veves et al., 1998) studies have suggested an attenuated vasodilator response to both 
ACh and SNP, indicative of impaired NO-mediated vasodilatation in type 2 diabetic 
patients. In contrast Sokolnicki et al., (2007), utilised intradermal microdialysis to 
employ potent NO blockade to assess NO contribution during whole body heating and 
reported no difference in the contribution of NO to cutaneous microvascular 
vasodilation between type 2 diabetic patients and matched controls. However, whole 
body heating only elicits ~30-40% contribution of NO to the cutaneous microvessel 
vasodilator response (Shastry et al., 1998; Wilkins et al., 2003), whereas, localised 
heating at 42°C elicits ~70% contribution of NO (Kellogg et al., 1999; Minson et al., 
2001). These data suggests that whole body heating does not interrogate the cutaneous 
microvessel NO vasodilator system as effectively as localised heating at 42°C. The 
current disparity in the literature could reflect the variability inherent in the disease 
itself, including the presence of peripheral neuropathy and the range of co-morbidities 
associated with type 2 diabetes. Alternatively, it could be a consequence of the 
inconsistency of techniques used to assess NO-mediated cutaneous microvessel function 
in type 2 diabetes. Most (Veves et al., 1998; Caballero et al., 1999; Wick et al., 2006), 
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but not all (Sokolnicki et al., 2007) of these studies have utilised iontophoresis which 
has well accepted limitations including the confounding effects associated with using an 
electrical current for drug administration into the skin, and individual variations of the 
electrical resistance characteristics of the skin barrier (Cracowski et al., 2006). The 
sensitivity of intradermal microdialysis interrogates the cutaneous circulatory system 
with greater accuracy than iontophoresis, which might explain why the findings of 
Sokolnicki et al., (2007) contradict the findings of previous studies that utilised 
iontophoresis to assess NO-mediated cutaneous microvessel function in type 2 diabetes.  
 
2.11 Current Treatment Strategies for NAFLD 
There is currently no effective pharmacological treatment in reducing hepatic steatosis, 
therefore investigation of alternative management strategies is warranted. Moderate 
weight loss as well as increased physical activity are associated with improvements in 
insulin sensitivity (Houmard et al., 2004; Petersen et al., 2005) and thus are logical 
treatment modalities for NAFLD patients.  
 
2.11.1 Diet & Exercise 
Lifestyle modification programs comprising a structured exercise and diet intervention 
are recommended as a non-pharmacological treatment to reduce hepatic fat in NAFLD 
patients (Harrison & Day, 2007). The largest study to investigate the combined 
therapeutic effect of diet and exercise was conducted by Kantartzis et al. (2009) who 
reported that after 9-months, a 2.2kg reduction in total body fat gave rise to a 31% 
decrease in hepatic fat relative to baseline (5.4±0.5 vs. 3.7±0.3%) in 170 overweight 
individuals. Fifty of these subjects exhibited NAFLD, in whom a 2.4kg reduction in 
total body fat and a 35% relative reduction in hepatic fat (13.0±0.9 vs. 8.4±0.8) were 
observed following the intervention. Importantly, prior to the intervention, 
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cardiorespiratory fitness was an independent predictor of hepatic fat, indicative that 
habitual fitness and hepatic fat are causally linked. Moreover, there was a strong 
correlation between improvements in cardiorespiratory fitness and hepatic fat reduction 
following the intervention. 
 
A modest reduction in body weight (~10% of initial body weight) following hypocaloric 
diet, or a combination of diet and exercise induced a 29-58% relative reduction in 
hepatic fat in overweight and obese individuals (Larson-Meyer et al., 2006; Shah et al., 
2009). Nevertheless, it has also been demonstrated that even mild weight loss (≤5% of 
initial body weight) following a combination of diet and exercise can provoke a 20-60% 
relative reduction in hepatic fat (Ueno et al., 1997; Tamura et al., 2005; Thomas et al., 
2006; Thamer et al., 2007; Kantartzis et al., 2009). These data indicate that following 
lifestyle modification, significant weight loss may not be an essential prerequisite to 
hepatic fat reduction and suggest that exercise may confer additional benefit. 
Nevertheless, it is very difficult to distinguish the effect of exercise per se from studies 
incorporating both exercise and diet as part of a lifestyle intervention.  
 
2.11.2 Exercise 
Evidence from a number of cross-sectional studies have suggested a significant inverse 
correlation between physical activity levels and/or cardiorespiratory fitness and hepatic 
fat content in NAFLD patients (Suzuki et al., 2005; Church et al., 2006; McMillan et 
al., 2007; Perseghin et al., 2007). Nevertheless, the effect of exercise alone on reducing 
hepatic fat in NAFLD patients is currently unclear as the limited studies available 
exhibit equivocal findings (Shojaee-Moradie et al., 2007; Bonekamp et al., 2008; 
Devries et al., 2008; Johnson et al., 2009; Finucane et al., 2010; van der Heijden et al., 
2010).  
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A randomised controlled trial conducted by Johnson et al. (2009) demonstrated a 
significant reduction in hepatic fat and VAT, independent of overall weight loss, in 
obese individuals following only 4-weeks of moderate/high intensity cycling exercise 
compared with a placebo group (sham exercise). Following this short-term exercise 
intervention, a mean relative reduction of 21% in hepatic fat was observed, whereas no 
change was seen in the placebo group. Similar findings have been demonstrated in 
obese adolescents, whereby 12-weeks of moderate intensity aerobic exercise stimulated 
~37% relative reduction in hepatic fat as well as a reduction in VAT without provoking 
weight loss (van der Heijden et al., 2010). Conversely, no change in hepatic fat or VAT 
was observed in lean adolescents following aerobic exercise training.  
 
Bonekamp et al. (2008) demonstrated a reduction in hepatic fat independent of weight 
loss following 24-weeks of moderate intensity aerobic and resistance exercise training 
in type 2 diabetic patients with NAFLD compared with controls. Interestingly, unlike 
the aforementioned studies, this reduction in hepatic fat was not accompanied by any 
change to VAT and was independent of a mild reduction in total body fat and waist 
circumference. Similarly, a randomised controlled trail conducted by Finucane et al. 
(2010) reported that 12-weeks of moderate intensity aerobic exercise training prevents 
the age related increase in hepatic fat in overweight men. However, it is important to 
note that these overweight subjects did not exhibit NAFLD (mean 3.7% 
intrahepatocellular triglyceride content), therefore, the clinical relevance of this finding 
to the NAFLD population is limited as these individuals are not at high risk of future 
liver disease and CVD.      
 
Although the aforementioned studies provide promising evidence that supports the 
utilisation of exercise as a treatment strategy in NAFLD, the therapeutic effect of 
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exercise on hepatic fat accumulation is not a unanimous finding. Indeed, studies by 
Shojaee-Moradie et al. (2007) and Devries et al. (2008) which adopted moderate 
intensity training protocols for six and twelve weeks respectively, both failed to 
significantly reduce hepatic fat. However, a noteworthy point regarding the Shojaee-
Maradie et al. (2007) observation is that the subjects in this study were overweight, but 
did not have NAFLD (mean 3.95% intrahepatocellular triglyceride content). 
Additionally, Devries et al. (2008) determined hepatic fat content via computed 
tomography, whereas, all other studies utilised 1H-MRS as the non-invasive gold 
standard technique (Cusi, 2009). Computed tomography determines hepatic fat content 
via highly qualitative and insensitive estimates of liver density (Stefan et al., 2008), 
which may explain why no changes in hepatic fat accumulation were detected in this 
study. 
 
The current literature provides valuable insight into the efficacy of exercise training in 
reducing intrahepatic triglyceride content in NAFLD patients, however, no previous 
study has utilised liver biopsies as the gold standard diagnostic technique to investigate 
the impact of exercise training on the histological severity of NAFLD. This would be of 
great clinical relevance as it would ascertain whether exercise training is capable of 
reducing hepatic inflammation and/or fibrosis and subsequently prevent the progression 
to cirrhosis and end stage liver disease in this high risk population.     
 
Importantly, the current evidence suggests that increased cardiorespiratory fitness or 
reduced intra-abdominal obesity following exercise training does not necessarily 
provoke a reduction in hepatic fat accumulation (Shojaee-Moradie et al., 2007; Devries 
et al., 2008). Furthermore, it would seem that exercise has the ability to provoke a 
reduction in hepatic fat content, irrespective of changes in body weight, body fat 
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(Johnson et al., 2009; Finucane et al., 2010; van der Heijden et al., 2010) and even 
VAT (Bonekamp et al., 2008). This latter observation suggests that exercise has an 
independent therapeutic effect on hepatic fat accumulation. Nevertheless, it is a 
remarkable fact that no previous study has compared the therapeutic impacts of 
supervised exercise training with the current conventional clinical care guidelines 
(weight loss and increased physical activity) on hepatic fat content in NAFLD patients. 
 
2.12 Exercise Training and FMD  
Exercise has been shown to improve the structure and function of arteries, by enhancing 
endothelial function and thus reducing the development of atherosclerosis (Kingwell & 
Jennings, 1997). Regular exercise training involves recurrent exposure to dramatic 
changes in haemodynamics, which subsequently increases the shear stress exerted on 
the arterial wall.  This shear stress mechanism promotes an increase in NO 
bioavailability by reducing the number of oxygen free radicals and up-regulating eNOS 
protein (Green et al., 2004a; Green et al., 2008). It is likely that shear stress is the 
predominant physiological stimulus accounting for the beneficial effect of exercise 
training on the vasculature. Collectively, these enhancements result in an increase in NO 
function which promotes efficient vasomotor function and decreases the risk of 
atherosclerotic development.  
 
Structured exercise training has been shown to enhance endothelial function in healthy 
individuals (Kingwell & Jennings, 1997; Clarkson et al., 1999; Goto et al., 2003).  
Nevertheless, it has been postulated that healthy individuals who exhibit well preserved 
endothelial function may be less susceptible to exercise-induced enhancements in FMD 
compared with individuals who demonstrate endothelial dysfunction (Green et al., 
2004a). Moreover, it has also been reported that in order to enhance endothelial function 
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in healthy individuals, large muscle group exercise is required as localised exercise 
involving only small muscle groups has limited impact on NO vasodilator function 
(Green et al., 2004b). This is likely due to the minimal haemodynamic stress associated 
with small muscle group exercise being insufficient to induce shear stress mediated 
improvements in NO function. 
 
The therapeutic effect of exercise training on endothelial dysfunction has been observed 
in numerous pathological states, several of which are frequently expressed by NAFLD 
patients (Higashi et al., 1999; Lewis et al., 1999; Lavrencic et al., 2000; Maiorana et al., 
2001; Walsh et al., 2003; Watts et al., 2004). A randomised crossover design study 
performed by Watts et al. (2004) reported that endothelial function, measured using 
FMD, was impaired in obese adolescents relative to lean controls and that eight weeks 
of moderate intensity circuit training normalised endothelial function. Similarly, 
Hambrecht and colleagues (2003) studied the effects of aerobic exercise training on 
endothelial function in coronary artery disease (CAD) patients, specifically in relation to 
the expression of eNOS. Training resulted in the up-regulation of eNOS and shear stress 
related eNOS phosphorylation compared with inactive controls, indicating that shear 
stress may be attributable for the increased NO bioavailability, and consequent 
enhanced FMD, observed with exercise training. 
 
Mairorana et al. (2001) conducted a randomised controlled trial which reported that a 
combination of predominantly lower-limb resistance and aerobic exercise training for 
eight weeks significantly improves endothelial dysfunction exhibited in type 2 diabetes 
compared with inactive matched controls. Improvements in brachial artery FMD were 
not associated with changes in fasting blood glucose or glycated haemoglobin, 
suggesting that exercise-induced enhancements in endothelial function occur 
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independently of changes to glycaemic control in type 2 diabetic patients. This study 
also demonstrated that predominantly lower limb exercise is capable of inducing an 
enhancement in (upper limb) brachial artery NO vasodilator response, indicative that 
exercise has a systemic effect on endothelial function. This finding has been 
corroborated by several other studies (Clarkson et al., 1999; Higashi et al., 1999; Lewis 
et al., 1999; Lavrencic et al., 2000).  
 
Exercise training has also been reported to improve endothelial function in individuals 
with the metabolic syndrome (Lavrencic et al., 2000). In this well designed study, 29 
male participants were randomly assigned to 12-weeks of high intensity cycle-
ergometer training or to a control group, whereby participants were asked to simply 
maintain their habitual physical activity levels for 12-weeks. Following exercise 
training, FMD significantly improved, whereas no changes were observed in endothelial 
function in the control group. These exercise mediated improvements in FMD occurred 
without any changes being observed in individual components of the metabolic 
syndrome, indicative that exercise has a direct therapeutic effect on the vasculature in 
individuals with metabolic syndrome. 
 
The consistency of the published data demonstrating exercise-induced improvements in 
the endothelial function of heterogeneous groups is remarkable, and contrasts with 
training studies involving healthy participants with normal endothelial function. This 
strongly suggests that subjects with impaired endothelial function may be more 
amenable to improvement in NO function as a result of training than healthy subjects. 
Interestingly, it has also been demonstrated that exercise-induced improvement in 
endothelial dysfunction is independent of changes in traditional markers of 
cardiovascular risk (Green et al., 2003). This is of particular importance to the NAFLD 
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population as cardiovascular risk factors such as obesity, insulin resistance and 
hyperlipidaemia are frequently expressed in this patient group. Nevertheless, the effect 
of regular exercise training on endothelial function within the NAFLD population has 
not been previously investigated, nor has the relative impact of current clinical care.  
 
2.13 Exercise training and NO-mediated cutaneous microvessel function  
Research work investigating the effect of cardiorespiratory fitness and exercise training 
on cutaneous microvascular NO function generally suggests that trained healthy 
individuals exhibit augmented cutaneous vasodilatator responsiveness to ACh 
(Kvernmo et al., 1998; Lenasi & Strucl, 2004; Wang, 2005). These findings are 
corroborated by limited evidence which suggests that the NO-mediated plateau phase of 
SKBF in response to localised heating is higher in trained individuals (Roche et al., 
2010), whereas, the predominantly axon reflex mediated initial peak is not influenced 
by training status (Tew et al., 2011). Interestingly, it has also been reported that 
exercise-induced improvements in ACh-mediated vasodilatation are abolished 
following an eight week detraining period (Wang, 2005) and that 14-56 days of bed rest 
confers an attenuated NO-mediated vasodilator response in the skin of normally active 
healthy individuals (Crandall et al., 2003; Demiot et al., 2007). Collectively, the current 
body of evidence suggests that fitness and/or physical activity promotes increased NO 
bioavailability in the cutaneous microvasculature of healthy individuals. 
 
Wang et al. (2005) illustrated that exercise had a therapeutic effect on cutaneous 
microvessel function in 10 young sedentary individuals. Plasma NO metabolites (nitrite 
plus nitrate) were measured by a microplate fluorometer and cutaneous microvascular 
perfusion responses to iontophoretically applied ACh and SNP were determined before 
and after 5-weeks of moderate intensity cycle-ergometer training. Following training, 
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plasma NO metabolite concentration and ACh-induced perfusion increased, suggestive 
of an improvement in cutaneous NO microvascular function. Similarly, Hodges et al. 
(2010) reported an increase in ACh-mediated SKBF following 24, 36 and 48 weeks of 
moderate aerobic intensity exercise in post-menopausal women. Surprisingly, this study 
also reported an increase in SNP-mediated SKBF after 36-weeks of exercise training, 
indicative that chronic exercise may induce structural changes to cutaneous 
microvessels. Although, the aforementioned studies provide valuable information 
regarding the impact of exercise training on cutaneous microvessel function, both study 
designs are limited as neither incorporated an inactive control group as a means of direct 
comparison. 
 
Currently, research investigating the effect of exercise on the cutaneous microvascular 
endothelial function of diseased populations is limited and conflicting in its findings. 
Klonizakis and colleagues (2009) conducted a randomised controlled trial and reported 
that eight weeks of moderate intensity exercise training elicits an augmented cutaneous 
vasodilator response to ACh when compared with inactive controls in chronic venous 
disease patients. In contrast, it would seem that exercise has little therapeutic effect on 
the microvasculature of type 2 diabetic patients. Indeed, it has been recently 
demonstrated that there is no difference in the NO-mediated vasodilator response to 
localized heating in self-reported physically active type 2 diabetic patients compared to 
their sedentary counterparts (Colberg et al., 2002). Moreover, it has also been observed 
that six months of aerobic exercise training does not improve the microvascular 
response to iontophoretically applied ACh or localised heating when compared with 
conventional care in type 2 diabetic patients (Middlebrooke et al., 2006). However, the 
training stimulus of the latter study did not induce an improvement in cardiorespiratory 
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fitness, which suggests the training stimulus was not of a sufficient intensity to elicit 
improvements in cutaneous NO-mediated microvessel function. 
 
Although elderly individuals are not regarded as a diseased population per se, the age 
related attenuation of cutaneous microvascular function is well documented (Holowatz 
et al., 2007). Recently, Black et al. (2008b) utilised intradermal microdialysis to elicit 
NO blockade and demonstrated that moderate intensity exercise prevents the age-related 
attenuation of cutaneous NO-mediated vasodilator response to both localised heating 
and Ach. Currently, this is the only study to investigate the mechanisms of the 
cutaneous vasodilator function via microdialysis with selective NO inhibitor pathways 
following exercise training in any population. 
 
2.14 Summary 
In summary, NAFLD is the most common form of chronic liver disease in western 
society, affecting approximately 20-30% of general population and ~70-90% of obese 
and type 2 diabetic individuals (Adams & Angulo, 2005; Marchesini et al., 2005; 
Neuschwander-Tetri, 2005). Conduit artery endothelial dysfunction, an early surrogate 
marker of CVD risk, is present in NAFLD, yet the mechanisms contributing to this 
dysfunction are incompletely understood. Excess abdominal VAT is highly prevalent in 
NAFLD and may contribute to endothelial dysfunction. NAFLD is a prediabetic 
condition, and therefore these patients are at high risk of microvascular complications 
that are associated with type 2 diabetes, such as neuropathy and retinopathy. 
Nevertheless, no research studies have been conducted on cutaneous microvessel 
endothelial function in this high risk group. Critically, CVD is the leading cause of 
death in NAFLD, however, the effect of exercise training on conduit artery and 
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microvessel endothelial function as a cardio-protective management strategy has not 
been previously investigated.   
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Chapter 3 
GENERAL METHODOLOGY 
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3.1 Participants 
Sedentary (<2 hours of exercise p/wk) NAFLD patients were recruited from the 
gastroenterology clinics at the Royal Liverpool University Hospital and the University 
Hospital Aintree and control individuals via local advertisement. The diagnosis of 
NAFLD was identified on the basis of chronically raised alanine aminotransferase 
(ALT) levels (>1.5 x upper normal values for 6-months or more) and confirmed upon 
the presence of ≥5.56%  intrahepatocellular triglyceride content with no evidence of 
cirrhosis as determined by proton magnetic resonance spectroscopy (1H-MRS) (see 
section 3.5.1 Proton magnetic resonance spectroscopy (1H-MRS)). In a small number of 
cases the diagnosis was confirmed histologically after liver biopsy. Other causes of liver 
disease were excluded via a complete laboratory investigation for viral hepatitis 
(hepatitis B and C viral markers), autoimmune hepatitis, primary biliary cirrhosis (non-
organ-specific antibodies), celiac disease (anti-gladin antibodies) and genetic diseases 
(α1 antitripsin, ceruloplasmin). All participants were non-smokers and non-diabetics 
who had no history of excessive alcohol intake as defined by an average weekly 
consumption of <14 units for females and <21 units for males. None of the participants 
had history of ischaemic heart disease or demonstrated any contraindications to 
exercise. None of the control individuals were taking any prescribed medication. The 
study conformed to the Declaration of Helsinki and was approved by the local research 
ethics committee (LREC) and research and development departments at all 
collaborating institutions. Participants were informed of the methods verbally and in 
writing before providing written informed consent. 
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3.2 Anthropometric Measurements 
Height was measured in a free-standing position to the nearest 0.5 cm using a measuring 
device (Seca, Model 220, Germany).  Body mass was measured to the nearest 0.05 kg 
using calibrated electronic digital scales (Seca, Model 767, Germany). From this, body 
mass index (BMI; mass (Kg) / (height (m)2) was calculated. Waist circumference was 
measured at the level of the umbilicus. Resting blood pressure (mm Hg) and resting 
heart rate (beats.min-1) were also determined from an average of three measures using 
an automated BP monitor (Dinamap, G & E Medical, Tampa, Florida).  
 
3.3 Fasting Blood Sample 
Fasting venous blood samples were drawn for the measurement of glucose. Lipid 
profiles including cholesterol, triglycerides, high-density lipoproteins (HDL) and low-
density lipoproteins, (LDL) were enumerated and cholesterol:HDL ratio was calculated. 
Serum liver enzymes including alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and gamma-glutamyltransferase (GGT) were also assessed. 
From these samples, reproductive hormone profiles were measured in pre-menopausal 
female participants including; follicle stimulating hormone (FSH), lutenizing hormone 
(LH), oestradiol, progesterone, testosterone, sex hormone binding globulin (SHBG) and 
free androgen index (FAI) was calculated (total testosterone / SHBG x 100). All blood 
samples were analysed by an experienced laboratory technician. 
 
3.4 Vascular Function 
All vascular function assessments were performed following an overnight fast, 12-hour 
abstinence from caffeine and a 24-hour abstinence from alcohol and strenuous exercise. 
Measurements were performed in a quiet, temperature controlled laboratory. Upon 
arrival, participants rested in the supine position for ~20 minutes before assessment 
52 
 
commenced. Following the rest period, HR and blood pressure were determined from 
an average of three measures using an automated BP monitor (Dinamap, G & E 
Medical, Tampa, Florida) on the left arm. Participants were then positioned with their 
right arm extended and immobilised with foam supports at an angle of ~80° from the 
torso. 
 
3.4.1 Flow-Mediated Dilation (FMD) 
A rapid inflation and deflation pneumatic device (D.E. Hokanson, Bellevue, WA) was 
used with an inflation cuff placed immediately distal to the olecranon process of the 
forearm of the imaged arm to provide a stimulus for forearm ischaemia (Corretti et al., 
2002). A 10-MHz multi frequency linear array probe attached to a high-resolution 
ultrasound machine (Siemens Acuson P50, Siemens Medical Solutions, USA) was 
utilised to image the brachial artery in the distal one third of the upper right arm. When 
an optimal image was acquired, the probe was held stable and the ultrasound parameters 
were set to optimise the longitudinal, B-mode images of the lumen-arterial wall 
interface. Continuous Doppler velocity assessment was also obtained using the high-
resolution ultrasound machine and was collected at an isonation angle of 60 degrees. 
Ultrasound images of arterial diameter and blood flow velocity were recorded real time 
using specialised recording software (Camtasia). A baseline recording lasting 1-minute 
was acquired before the forearm cuff was inflated (~220 mmHg) for 5-minutes. Artery 
diameter and blood flow velocity recordings resumed 30 seconds prior to cuff deflation 
and continued for 3-minutes thereafter. Peak brachial artery diameter and blood flow 
velocity, and the time taken to reach these peaks following cuff release were recorded. 
The response immediately following cuff release (hyperaemia) is a reflection of brachial 
artery endothelial-dependent function and is expressed as FMD %.  
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3.4.2 Glyceryl Tri-Nitrate (GTN) 
A further 15 min rest period followed, before the brachial artery was imaged once more. 
A 1-min baseline recording of diameter and velocity flow was conducted before the 
sub-lingual administration GTN, a potent NO donor. GTN forms as NO, causing a 
generalised vasodilatation. As such, GTN provides an endothelial-independent source of 
NO with which it challenges the integrity of the smooth muscle and thereby provides an 
insight of smooth muscle sensitivity and a subsequent short-term increase in blood flow 
velocity and arterial diameter. The brachial artery was imaged for 10-min following 
administration of GTN. 
 
3.4.3 Brachial artery diameter and blood flow analysis 
Analysis of brachial artery diameter was conducted using custom designed edge-
detection and wall-tracking software, which is largely independent of investigator bias 
(Woodman et al., 2001). Briefly, the image was taken directly from the ultrasound 
machine and saved as an AVI file on a PC. Subsequent software analysis of this data 
was performed at 30Hz using an icon-based graphical programming language and 
toolkit (LabVIEW 6.02, National Instruments). The initial phase of image analysis 
involved the identification of regions of interest (ROI) on the first frame of every 
individual study.  These ROIs allowed automated calibration for diameters on the B-
mode image (Figure 3.1) and velocities (Figure 3.2) on the Doppler strip. An ROI was 
then drawn around the optimal area of the B-mode image. Within this ROI a pixel-
density algorithm automatically identified the angle-corrected near and far wall e-lines 
for every pixel column within the ROI. The algorithm begins by dividing the ROI into 
an upper half, containing the near wall lumen-intima interface, and a lower half 
containing the far wall interfaces. The near wall intimal edge is identified by a Rake 
routine that scans from the bottom to the top of the upper half of the ROI. The position 
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of the edge is established by determining the point where the pixel intensity changes 
most rapidly. Typical B-mode ROIs therefore, contained approximately 200 to 300 
diameter measures per frame, the average of which was calculated and stored. This 
process transpired at 30 frames per second. A final ROI was drawn around the Doppler 
waveform and automatically identified the peak of the waveform. The mean diameter 
measures derived from within the B-mode ROI were then synchronised with the 
velocity measure derived from the Doppler ROI at 30 Hz. Ultimately, from this 
synchronised diameter and velocity data, blood flow (the product of lumen cross-
sectional area and Doppler velocity and shear rate (4 times velocity divided by 
diameter) were calculated at 30 Hz (Black et al., 2008a). 
 
All data were written to file and retrieved for analysis in a custom-designed analysis 
package. It has been previously demonstrated that reproducibility of diameter 
measurements using this semi-automated software is significantly better than other 
manual methods, significantly reduces observer error, and possesses an intra-observer 
CV of 6.7% (Woodman et al., 2001). Furthermore, our method of blood flow 
assessment is closely correlated with actual flow through a “phantom” arterial flow 
system (Green et al., 2002). 
 
Figure 3.1 2D B-Mode Ultrasound image recording of the brachial artery in the 
analysis software with ROI highlighted.  
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Figure 3.2 Blood flow velocity trace. 
 
3.4.4 Vascular Data Analysis 
Baseline diameter, flow, and shear rate were calculated as the mean of data acquired 
across the 1 minute baseline period preceding cuff inflation.  Peak diameter following 
cuff deflation was automatically detected according to an algorithm which identified the 
maximum bracket of data subsequent to performance of a moving window smoothing 
function. This smoothing routine calculates the median value from 100 consecutive 
samples before the window shifts to the next bracket of data, which shares 20% overlap 
with the preceding bracket. The maximum value of all the calculated median values is 
then automatically detected and chosen to represent the peak of the post-deflation artery 
diameter curve. FMD was calculated as the percentage rise of this peak diameter from 
the preceding baseline diameter.  The time to peak diameter (in seconds) was calculated 
from the point of cuff deflation to the maximum post-deflation diameter. Calculation of 
FMD and time to peak were therefore observer-independent and based on standardised 
algorithms applied to data which had undergone automated edge-detection and wall-
tracking analysis.  
 
In accordance with recent findings (Pyke & Tschakovsky, 2007), we calculated the 
shear rate  stimulus responsible for endothelium-dependent FMD.  The post-deflation 
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shear rate data, derived from simultaneously acquired velocity and diameter measures at 
30 Hz, was exported to a spread sheet and the area under the shear rate curve (AUC) 
calculated for data up to the point of maximal post-deflation diameter (FMD) for each 
individual using the trapezoid rule.   
 
3.5 Magnetic Resonance Methodology 
All participants underwent magnetic resonance imaging (MRI) in a 1.5T Siemens 
Symphony scanner (Siemens Medical Solutions, Erlangen, Germany) in a prone 
position, being moved through the magnet to acquire full body coverage. Scans were 
anonymised prior to analysis thus ensuring the observer was blinded to all clinical 
details 
 
3.5.1 Proton magnetic resonance spectroscopy (1H-MRS) 
In liver, NAFLD was defined as intrahepatocellular triglyceride content (IHTC) ≥ 
5.56% (Szczepaniak et al., 2005). Transverse images of the liver were used to ensure 
accurate positioning of the three voxels in standard sites of the liver, avoiding ducts and 
vasculature (Figure 3.3). Single voxel spectroscopy was conducted at each of these three 
sites. Voxel size was 20x20x20 mm, TE 135 ms, TR 1500 ms, with 64 acquisitions. 
Voxel placement in post-treatment studies was guided by reference to the pre-treatment 
images. 1H MR spectra were quantified using the AMARES algorithm in the software 
package jMRUI-3.0 (Vanhamme et al., 1997; Naressi et al., 2001). As previously 
described, IHTC is expressed as % of CH2 lipid signal amplitude relative to water signal 
amplitude after correcting for T1 and T2 (Thomas et al., 2005)(Figure 3.4). T1 and T2 
values for IHTC were obtained by an experienced physicist. 
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Figure 3.3 Example of the voxel positions used during liver spectroscopy. 
 
 
 
Figure 3.4 Percentage ratio of the CH2 lipid peak area relative to the water peak area. 
 
3.5.2 Volumetric analysis of abdominal subcutaneous and visceral fat 
Abdominal subcutaneous adipose tissue (SAT) and abdominal visceral adipose tissue 
(VAT) was calculated from whole body axial T1-weighted fast spin echo scans (axial 
scans, 10 mm slice thickness followed by a 10 mm gap using the integral body coil). 
The abdominal region was defined as the image slices from the slice containing the 
femoral heads, to the slice containing the top of the liver/base of the lungs (Figure 3.5). 
All scans were analysed centrally using ANALYZE 4.0; CN software (Rochester, MN, 
USA).  
        Chemical shift/ppm 
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Figure 3.5 One trans-axial image of abdomen. Area highlighted in green represent 
abdominal subcutaneous fat and area highlight in red represent abdominal visceral fat. 
 
 
3.6 Maximal Oxygen Consumption Test (VO2peak) 
 A fitness test (VO2peak) was performed to quantify aerobic capacity. This comprised of 
a 2 minute warm up followed by an incremental exercise to volitional exhaustion 
performed on a treadmill ergometer (H/P/ Cosmos, Pulsar 4.0, Nussdorf-Traunstein, 
Germany) in a temperature controlled environment (Bruce et al., 1973). Following a 2-
min warm up at 2.2 Km.h-1 on a flat gradient, the initial workload was set at 2.7 Km.h-1 
at 5° grade. Thereafter, step-wise increments in speed and grade were employed every 
minute (modified Bruce protocol). Heart rate was continuously measured (Polar Electro 
Oy, Finland) and the participants condition was monitored using the BORG scale 
(Burkhalter, 1996; Borg, 1998). Prior to commencing the cardiorespiratory exercise test, 
all patients above the age of 55 years had electrocardiogram (ECG) electrodes attached 
to their chest so the heart could be monitored throughout the test; this is in keeping with 
the American College of Sport Medicine (ACSM) exercise prescription guidelines.  
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VO2peak during exercise was calculated from minute ventilation, measured using a 
pneumotach and simultaneous breath-by-breath analysis of expired gas fractions 
(Medgraphics CPX/D and Ultima CardiO2 Systems, Minnesota). Gas analysers and 
flow probes were calibrated before each test.  Oxygen consumption was recorded during 
the final 40 sec of each stage of the test and expressed relative to body weight (ml.kg-
1.min-1). Peak oxygen consumption was calculated as the highest consecutive 10 second 
period of gas exchange data occurring in the last minute before volitional exhaustion, 
which generally occurred due to leg fatigue or breathlessness.  
 
3.7 Supervised Exercise Training Intervention   
The exercise training program consisted of 16-weeks of progressive moderate intensity 
aerobic exercise.  Prior to commencing the exercise training, all participants attended a 
full familiarisation session at the University gymnasium as well as a comprehensive 
induction at their local recreational gymnasium. Exercise sessions were fully supervised 
at least once a week by a dedicated exercise physiologist (CP) within the University 
gymnasium. It was at this training session that participants were issued a weekly 
progressive exercise protocol that was specific to their basal fitness level and rate of 
progression. In addition, a polar heart rate monitor was used to continuously monitor 
heart rate at all supervised sessions. 
 
Training comprised of a combination of treadmill and cycle ergometer based exercise 
with the intensity and duration of exercise sessions progressively increasing during the 
course of the intervention. Participants underwent 30 minutes of moderate intensity 
aerobic exercise 3 times a week at 30% heart rate reserve (HRR) for the initial 4 weeks. 
Intensity increased to 45% HRR for the following 4 weeks, until week 8, where HRR 
remained at 45%, but the duration of each session increased to 45 minutes. For the final 
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4 weeks the intensity increased to 60% HRR and each 45 minute session was performed 
5 times per week (Figure 3.6). HRR was calculated using the following formula: ((Max 
HR – Resting HR) × Intensity) + Resting HR. The resting and maximal heart rate 
measures were derived from a maximal exercise test undertaken prior to, and following 
the baseline VO2peak assessment.  
 
Figure 3.6 16-week moderate intensity exercise training protocol. 
 
To facilitate maximum compliance to the exercise protocol throughout the 16-week 
period, all participants were closely monitored to ensure that they maintained their 
prescribed rate of perceived exertion (RPE) and HR during supervised sessions. All 
exercise sessions that were performed at the local recreational gymnasium were 
monitored using the techno-gym wellness key system. An electronic database key was 
allocated to each participant, onto which the exercise physiologist uploaded a weekly, 
tailored, exercise training protocol.  Once entered into a cardiorespiratory machine, the 
key automatically started the machine to the uploaded intensity. Moreover, the key 
recorded every training session performed in the recreational gymnasiums ensuring the 
correct HRR was maintained and that each participant was compliant during non-
supervised sessions. No dietary alterations were made by any participant throughout the 
exercise intervention; this was assessed using a standard food diary. 
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3.8 Conventional Care Intervention 
Conventional care consisted of typical lifestyle advice provided at clinical consultation 
for a 16-week period. Participants were simply advised by their hepatologist or clinic 
nurse to modify their lifestyle by losing weight and increasing their physical activity. At 
no point was any supervision or guidance given to participants undertaking 
conventional care. 
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Chapter 4 
THE IMPACT OF HEPATIC FAT AND 
ABDOMINAL VISCERAL ADIPOSE TISSUE ON 
ENDOTHELIAL FUNCTION IN NAFLD PATIENTS 
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4.1 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is regarded as the hepatic manifestation of 
the metabolic syndrome and is closely associated with obesity, insulin resistance, and 
traditional cardiovascular disease (CVD) risk factors such as hypertension and 
hyperlipidaemia (Rector et al., 2008). CVD is the leading cause of death in NAFLD 
patients, exceeding that of liver related death (Ekstedt et al., 2006; Ong et al., 2008). 
Endothelial function, measured using the flow mediated dilatation (FMD) technique, is 
an early clinical marker of CVD. Previous studies have reported impaired FMD in 
NAFLD patients when compared to age and sex matched controls (Schindhelm et al., 
2005; Villanova et al., 2005). Moreover, as the severity of NAFLD progresses from 
steatosis to NASH, the level of impairment in FMD has been shown to increase 
(Villanova et al., 2005) and, ultimately, reduction in endothelium-independent dilatation 
becomes apparent (Senturk et al., 2008). This suggests that as the disease progresses, 
the detrimental influence on the vasculature is greater and may extend from the 
endothelium to vascular smooth muscle. 
 
It is well established that abdominal obesity is frequently expressed in NAFLD (Adams 
& Angulo, 2005; Angulo, 2007; Schreuder et al., 2008). Specifically, excess visceral 
adipose tissue (VAT) is considered a pivotal feature in the pathogenesis of NAFLD and 
is predictive of CVD (Despres, 2007; Petta et al., 2009). Several reports have 
demonstrated that obesity (Hashimoto et al., 1998; Arcaro et al., 1999; Baldeweg et al., 
2000; Joseph et al., 2002; Williams et al., 2005; Williams et al., 2006), insulin 
resistance (Balletshofer et al., 2000; Prior et al., 2005) and VAT (Hashimoto et al., 
1998; Romero-Corral et al., 2010) attenuate FMD. In addition, Villanova and 
colleagues (2005) demonstrated that impaired FMD in NAFLD was associated with 
insulin resistance and obesity. However, it is difficult to discern between the impacts of 
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obesity and insulin resistance in this study as BMI was the sole index of obesity and the 
control group was not matched for BMI. Despite widespread utilisation, BMI does not 
provide a comprehensive assessment of obesity status as it cannot distinguish between 
adipose and lean tissue (Oreopoulos et al., 2011), nor the impact of obesity on intra-
hepatic triglyceride content (IHTC) or abdominal VAT.  
 
No previous research has quantified IHTC and VAT via the non-invasive gold standard 
1H-MRS and MRI techniques respectively to investigate the impacts of these variables 
on FMD in NAFLD. Therefore, the aims of this study were to (i) investigate the extent 
of endothelial dysfunction in NAFLD patients compared to age and BMI matched 
controls; and (ii) to examine the impact of IHTC and abdominal VAT on endothelial 
function. It was hypothesised that (i) endothelial function would be impaired in NAFLD 
patients when compared with BMI-matched controls and (ii) endothelial dysfunction in 
NAFLD patients would be mediated by IHTC and abdominal VAT. 
 
4.2 Methods 
4.2.1 Participants 
Thirty two sedentary NAFLD patients (21 males, 11 females, 48±2yrs, BMI 
31±1kg/m2) and eighteen matched controls (8 males, 10 females, 48±2yrs, BMI 
30±1kg/m2) were recruited (For inclusion and exclusion criteria, please refer to General 
Methodology, Chapter 3). All NAFLD patients were normocholesterolaemic and 7 were 
taking anti-hypertensive medication (β-blocker n=3, ACE inhibitor n=2, Calcium 
channel blocker n=2). None of the controls were taking any prescribed medication. Pre-
menopausal women (n=4) were tested during the early follicular phase of the menstrual 
cycle, defined as day 1-7. 
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4.2.2 Research Design and Physiological Measures 
Participants were required to attend the laboratory for a number of physiological 
examinations, which included anthropometric assessments, a blood sample, assessment 
of brachial artery function, a cardiorespiratory fitness test and magnetic resonance 
imaging (MRI) with proton magnetic resonance spectroscopy (1H-MRS) to determine 
abdominal fat deposition and IHTC (for details of measurement procedures, please refer 
to general methodology, Chapter 3). Measurements were performed following an 
overnight fast, 12-hour abstinence from caffeine and 24-hour abstinence from alcohol 
and strenuous exercise.  
 
4.2.3 Statistical Analysis 
The primary outcome variable was FMD (%) between NAFLD and control individuals. 
Following analysis of distribution, differences between NAFLD and controls were 
compared using independent t-tests or non-parametric equivalent (Wilcoxon) for all 
variables. Pearson’s correlation coefficients (two-tailed) were calculated to evaluate 
relationships between FMD and all other major variables. Differences in FMD between 
NAFLD and controls were analysed using analysis of covariance with abdominal VAT 
as a covariate. Data were analysed using the SPSS 17.0 (SPSS, Chicago, Illinois) 
software. Data are presented in the text as mean±SE, unless otherwise stated and exact 
P values are cited (values of P of “0.000” provided by the statistics package are reported 
as “<0.0005”). 
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4.3 Results 
4.3.1 Clinical and biochemical characteristics 
The characteristics of all NAFLD and control participants are listed in Table 4.1. 
NAFLD patients and controls were matched for age, BMI and cardiorespiratory fitness 
(P>0.20), however, NAFLD patients exhibited an increased waist circumference 
(106.9±1.8 vs. 101.1±2.3cm; P=0.04). IHTC (27.2±3.0 vs. 2.9±0.4%; P<0.0005; Figure 
4.1) and serum liver enzymes were elevated in NAFLD patients (P<0.006; Table 4.1) as 
was abdominal VAT when compared with controls (P<0.0005; Figure 4.2). Fasting 
glucose did not differ between NAFLD and controls. Serum triglycerides were elevated 
(2.2±0.2 vs. 1.5±0.2 mmol.L-1; P<0.0005) and HDL reduced (1.3±0.1 vs. 1.5±0.1 
mmol.L-1; P=0.03) in NAFLD patients compared with controls (P<0.03). 
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Table 4.1 Characteristics of NAFLD and control participants. 
 NAFLD Controls P Value 
Anthropometrics    
  N (m/f) 21/11 8/10 n/a 
  Age (yrs) + 
   Weight (kg) 
49 (15) 
90.3±2.5 
48 (13) 
84.8±3.4 
0.81 
0.20 
  BMI (kg/m2) 31±1 30±1 0.20 
  Waist circumference (cm) + 105.2 (14.9) 100.3 (14.2)   0.04* 
  Systolic blood pressure (mmHg) 127±2 127±2 0.91 
  Diastolic blood pressure (mmHg) 79±1 77±2 0.74 
Hepatic and Body Fat Deposition    
  IHTC (%)++ 27.2±3.0 2.9±0.4 <0.0005* 
  Abdominal VAT (l) 5.4±0.3 3.4±0.2   <0.0005* 
  Abdominal Subcutaneous Fat (l) ++ 8.5±0.5 8.2±0.8     0.47 
Liver Enzymes    
  ALT (u/L) + 59 (60) 24 (24) <0.0005* 
  AST (u/L) + 36 (22) 24 (6) <0.0005* 
  GGT (u/L) + 50 (57) 23 (31) 0.006* 
Glucose and Lipid Profile    
   Fasting Glucose (mmol.L-1)  5.1±0.1 5.0±0.1 0.45 
   Cholesterol (mmol.L-1) 5.5±0.2 5.2±0.2 0.27 
   Triglyceride (mmol.L-1) ++ 2.2±0.2 1.5±0.2 <0.0005* 
   HDL (mmol.L-1) 1.3±0.1 1.5±0.1   0.03* 
   LDL (mmol.L-1) 3.3±0.1 3.3±0.3 0.89 
   Chol:HDL ratio + 4.0 (1.0) 4.0 (1.0) 0.06 
Cardiorespiratory Capacity    
   VO2Peak (ml/kg
-1/min-1) ++ 28.0±1.4 27.5±2.0 0.72 
Brachial Artery Vascular Function     
   Flow-Mediated Dilation (%)  4.8±0.3 8.3±0.7 <0.0005* 
   Baseline Diameter (mm) 4.2±0.02 4.1±0.02 0.81 
   Peak Diameter (mm) 4.3±0.02 4.5±0.02 0.65 
  Shear rateAUC (s
-1×103) 14.7±1.9 15.5±2.0 0.70 
  FMD- Mediated Time to Peak (s) 61.6±5.7 45.0±4.0   0.05* 
  GTN-Mediated Dilation (%) 
  GTN-Mediated Time to Peak (s) 
16.7±1.3 
387.5±17.9 
16.7±1.0 
330.0±35.6 
0.98 
0.27 
+ Non-parametric data presented as median (interquartile range). 
++ Logarithmically transformed data.  
* Significant difference between NAFLD vs. controls (P<0.05). 
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Figure 4.1 Individual IHTC data in NAFLD patients vs. BMI-matched controls (red 
markers represent the mean IHTC of the respective groups). 
 
 
 
Figure 4.2 Individual abdominal VAT data in NAFLD patients vs. BMI-matched 
controls (red markers represent the mean abdominal VAT of the respective groups). 
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4.3.2 Vascular measurements 
Brachial artery FMD% was significantly impaired in NAFLD patients when compared 
with BMI-matched controls (4.8±0.3 vs. 8.3±0.7%, P<0.0005, Figure 4.3). No 
differences were observed in baseline brachial artery diameter, peak diameter or shear 
rate between NAFLD patients and controls (P>0.65; Table 4.1). Nevertheless, it took 
NAFLD patients significantly longer to reach peak diameter (61.6±5.7 vs. 45.0±4.0s; 
P=0.05). No difference in endothelium-independent vasodilatation to GTN was 
observed (P=0.92) or endothelium independent time to peak (P=0.27; Table 4.1).  
 
 
 
Figure 4.3 Individual FMD data in NAFLD patients vs. BMI-matched controls (red 
markers represent the mean FMD of the respective groups). According to published 
prognostic data by Inaba et al., (2010) these data indicate that NAFLD patients are 
~21% more likely to suffer a cardiovascular event than BMI-matched controls. 
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4.3.3 FMD correlations 
A moderate inverse correlation was observed between FMD and abdominal VAT (r = -
0.48, P=0.01; Figure 4.4) in NAFLD patients, although no relationship was observed in 
control participants (r = -0.07, P=0.78; Figure 4.4). FMD did not correlate with any 
other variable in NAFLD patients or control participants (P>0.05). 
 
 
Figure 4.4 The relationship between FMD and abdominal VAT in NAFLD patients (r = 
-0.48, P=0.01) and BMI-matched controls (r = -0.07, P=0.78). 
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Impairment in FMD remained in NAFLD patients following independent covariate 
adjustment for abdominal VAT (5.0±0.5 vs. 7.3±0.7%, P=0.01; Figure 4.5).  
 
 
 
Figure 4.5 FMD response of NAFLD patients vs. BMI-matched controls after 
adjustment for abdominal VAT. 
 
4.4 Discussion 
The primary aim of the study was to investigate the impact of fat deposition on FMD in 
NAFLD and specifically, to establish whether abdominal VAT and/or IHTC had an 
independent detrimental impact on endothelial function. The major novel findings of 
this study were that (i) FMD was impaired in obese NAFLD patients compared with age 
and BMI matched controls; and (ii) the impairment in FMD is not explained by excess 
IHTC or abdominal VAT.  
 
Prior to adjustment, a significant mean reduction in FMD of 3.5% was observed in 
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relevant as recently published risk ratios indicate that the risk of a cardiovascular event 
increases by 21% for every 1 standard deviation (=3.5%) decrease in FMD (Inaba et al., 
2010), Subsequently, the findings of this chapter infer that NAFLD patients are 21% 
more likely to experience a cardiovascular event than individuals without NAFLD who 
are of a similar age, fitness and BMI. Following adjustment for abdominal VAT, the 
impairment in FMD exhibited by NAFLD patients reduced. Although, adjustment for 
abdominal VAT did not totally abolish the impairment in FMD, it appears to modestly 
contribute to NO-mediated endothelial dysfunction. Surprisingly, elevated IHTC in 
isolation had a negligible impact on FMD. Taken together, these findings suggest that 
neither excess IHTC nor abdominal VAT are key contributing factors to the endothelial 
dysfunction present in NAFLD. A previous study by Villanova et al. (2005) elegantly 
demonstrated that impaired FMD in NAFLD was associated with, but not explained by, 
insulin resistance. Nevertheless, VAT has been previously reported to be closely linked 
with the severity of NAFLD independent of insulin resistance (van der Poorten et al., 
2008). Given that isolated hallmark features of NAFLD such as IHTC, abdominal VAT 
and insulin resistance do not totally explain the decrement in FMD, other less overt 
pathological features may contribute to endothelial dysfunction, such as the excess 
secretion of inflammatory cytokines, including TNF-α and leptin.  
 
Previous research has demonstrated that FMD is impaired in NAFLD patients when 
compared with overweight (Vlachopoulos et al., 2010) age-matched (Villanova et al., 
2005; Senturk et al., 2008)  controls. Nevertheless, this is the first study to demonstrate 
that FMD is impaired in obese NAFLD patients when compared with BMI-matched 
obese controls (i.e. BMI>30). Moreover, this is the first study to employ the FMD 
technique according to the latest guidelines (Thijssen et al., 2011) which include 
measurement of the eliciting shear rate stimulus and absolute arterial diameters. Thus, a 
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novel finding of the current study is that the time to reach peak diameter following 
forearm ischaemia was significantly greater in NAFLD patients. However, following 
sub-lingual administration of a potent NO donor, time to reach peak arterial diameter 
was similar between groups. This suggests that NAFLD patients exhibit reduced 
endothelial hormone production rather than delayed relaxation of the smooth muscle in 
response to NO (Black et al., 2008a). This finding confirms that NAFLD patients 
demonstrate impaired endothelium-dependent vasodilator function. Another noteworthy 
observation is that NAFLD patients and controls were matched for cardiorespiratory 
fitness. Previous studies have suggested that cardiorespiratory fitness independently 
predicts the risk of CVD mortality (Sui et al., 2007; Ekblom-Bak et al., 2009). 
Nevertheless, fitness did not influence FMD in the current study, which supports the 
findings of Davison et al. (2010), who observed no association between 
cardiorespiratory fitness and FMD in lean and obese sedentary individuals. 
 
NAFLD patients demonstrated a larger waist circumference and exhibited elevated 
abdominal VAT compared with control participants, despite being matched for BMI. 
VAT is considered a pivotal feature in the pathogenesis of NAFLD as it is a key source 
of circulating adipokines, and is also predictive of CVD (Despres, 2007; Petta et al., 
2009). Moreover, VAT positively correlates with steatosis (Kelley et al., 2003; Nguyen-
Duy et al., 2003), hepatic insulin resistance (Miyazaki et al., 2002) and is closely linked 
with the severity of NAFLD, independent of insulin resistance (van der Poorten et al., 
2008). One recent study reported that a modest increase in VAT (47.3±31.4 to 
60.1±35.0cm2) promoted endothelial dysfunction in healthy individuals (Romero-Corral 
et al., 2010). Indeed, VAT has been reported to be a determinant of endothelial 
dysfunction, independent of traditional risk factors or liver steatosis in morbidly obese 
individuals (Sturm et al., 2009). However, the study of Sturm et al. (2009) employed 
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ultrasound to determine VAT and hepatic steatosis; a highly operator-dependent 
approach which is unable to quantify the degree of steatosis (Joy et al., 2003).  
 
In summary, FMD is impaired in obese NAFLD patients when compared with BMI 
matched controls, however, this impairment is not explained by excess IHTC or 
abdominal VAT. 
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Chapter 5 
A RANDOMISED CONTROLLED TRIAL 
COMPARING THE EFFECTS OF SUPERVISED 
EXERCISE TRAINING WITH CONVENTIONAL 
CLINICAL CARE ON ENDOTHELIAL 
FUNCTION IN NAFLD PATIENTS  
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5.1 Introduction 
Non-alcoholic fatty liver disease (NAFLD), characterised by elevated triglycerides 
within the liver, is the most common form of chronic liver disease in western society, 
affecting approximately 20-30% of the general population (Bedogni et al., 2005) and up 
to ~70-90% of obese and diabetic individuals (Adams & Angulo, 2005).  Although 
NAFLD is primarily a hepatic disorder, excess liver triglyceride accumulation is an 
independent risk factor for cardiovascular disease (CVD), insulin resistance and type 2 
diabetes (Stefan et al., 2008). Moreover, epidemiological research indicates that CVD is 
the leading cause of mortality in NAFLD patients, responsible for 25% of deaths, a 
value exceeding that of liver disease per se, which accounts for just 6% of mortality 
(Ong et al., 2008).  
 
Despite the increasing prevalence of NAFLD, therapeutic options are limited, with no 
effective pharmacological treatment to reduce hepatic fat. Lifestyle interventions 
including structured exercise and diet are therefore recommended to reduce hepatic fat 
in NAFLD patients (Caldwell & Lazo, 2009). Evidence from a number of cross-
sectional studies suggests a significant inverse correlation between physical activity 
levels and/or cardiorespiratory fitness and hepatic fat in NAFLD patients (Suzuki et al., 
2005; Church et al., 2006; McMillan et al., 2007; Perseghin et al., 2007). Moreover, a 
number of studies indicate that exercise training reduces hepatic fat in NAFLD patients 
(Bonekamp et al., 2008; Johnson et al., 2009; van der Heijden et al., 2010). 
Nevertheless, no study to date has compared the therapeutic effect of exercise with that 
of the general lifestyle advice provided as part of conventional clinical care on hepatic 
fat. 
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The impact of lifestyle modification or supervised exercise training on endothelial 
function, an early atherosclerotic marker which predicts future cardiovascular events, 
has not been investigated in NAFLD patients.  Exercise training has been shown to 
improve endothelial function in healthy individuals (Green et al., 2004a; Thijssen et al., 
2010) and in populations demonstrating risk factors for CVD (Higashi et al., 1999; 
Lewis et al., 1999; Lavrencic et al., 2000; Maiorana et al., 2001; Walsh et al., 2003; 
Watts et al., 2004). Importantly, exercise-induced improvements in endothelial function 
have been shown to occur both prior to, and independent of, changes in traditional 
markers of cardiovascular risk (Green et al., 2003). This is of particular importance to 
the NAFLD population as CVD risk factors such as obesity, insulin resistance and 
hyperlipidaemia are frequently exhibited and contribute to the higher CV mortality in 
this patient group. Therefore, the aim of this study was to compare the effect of a 
supervised exercise intervention with conventional clinical care on endothelial function 
in NAFLD patients. It was hypothesised that 16-weeks of supervised exercise training 
would induce a greater improvement in endothelial function in NAFLD patients when 
compared with 16-weeks of conventional clinical care.  
 
5.2 Methods 
5.2.1 Participants 
Twenty eligible NAFLD patients (11 males, 9 females, 49±3yrs, BMI 30±1kg/m2) 
completed the study (Figure 5.1). All NAFLD patients were normocholesterolaemic and 
6 were taking anti-hypertensive medication (β-blocker n=3, ACE inhibitor n=2, 
Calcium channel blocker n=1). Medications were not altered during the course of the 
study. All female participants were post-menopausal, except one, who had undergone a 
hysterectomy. 
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Figure 5.1 Participant flow diagram 
 
5.2.2 Research Design 
A series of physiological measurements were performed at baseline. Following this, 
NAFLD patients were randomly assigned to either 16-weeks of supervised and 
structured exercise training (n=13, 50±3yrs, BMI 30±1kg/m2) or to 16-weeks of 
conventional care (n=7, 47±6yrs, BMI 31±2kg/m2) (for details of respective 
interventions, please refer to General Methodology; Chapter 3). Upon completion of 
this 16-week period, all measurements were repeated. 
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5.2.3 Experimental Protocol 
Participants reported to the laboratory to undertake the baseline measurements including 
anthropometric assessment, a blood sample, assessment of brachial artery endothelial 
function, a cardiorespiratory fitness test and magnetic resonance imaging (MRI) with 
proton magnetic resonance spectroscopy (1H-MRS) to determine abdominal fat 
deposition and intrahepatocellular triglyceride content (IHTC) (for details of 
measurement procedures, please refer to general methodology, Chapter 3). 
Measurements were performed following an overnight fast, 12-hour abstinence from 
caffeine and 24-hour abstinence from alcohol and strenuous exercise.  
 
5.2.4 Statistical Analysis 
The primary outcome variable for this study was FMD (%) and the primary comparison 
was the effect of exercise vs. conventional care. For the comparison of the exercise vs. 
the conventional care intervention, delta (Δ) change from pre-intervention was 
calculated and analysed using analysis of covariance (ANCOVA), with pre-exercise 
data as a covariate. Pearson’s correlation coefficients (two-tailed) were calculated to 
evaluate relationships between delta (Δ) change in FMD and the delta (Δ) change in all 
other major variables. Data were analysed using the SPSS 17.0 (SPSS, Chicago, 
Illinois) software. Data are presented in the text as mean±SE, unless otherwise stated 
and exact P values are cited (values of P of “0.000” provided by the statistics package 
are reported as “<0.0005”). 
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5.3 Results 
NAFLD patients who were randomised to supervised exercise training demonstrated 92% 
compliance to exercise sessions. 
 
5.3.1 Cardiorespiratory Fitness 
Cardiorespiratory fitness increased by 7.0±1.5ml.kg-1.min-1 following exercise training, 
but, decreased by 2.3±2.1ml.kg-1.min-1 following conventional care (P=0.002; Table 
5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
Table 5.1 Changes in the characteristics of NAFLD patients following supervised exercise training and conventional clinical care. 
  Pre Ex Post Ex ∆ Ex Pre CC Post CC ∆ CC P value 
Anthropometrics 
Weight (kg) 86.7±3.3 84.5±3.5 -2.1 91.3±8.0 90.2±8.1 -1.2 0.31 
BMI (kg/m2) 30±1 29±1 -0.8 31±2 30±2 -0.4 0.29 
Waist circumference (cm)  103±2 99±2 -4.5 107±5 105±6 -1.9 0.17 
Systolic blood pressure (mmHg) 127±3 126±2 -0.8 125±5 124±4 -1.9 0.74 
Diastolic blood pressure (mmHg) 79±2 78±1 -0.4 76±3 74±1 -1.3 0.82 
Body Fat Deposition 
 
IHTC (%) 27.0±5.7 18.0±3.2 -8.8 25.2±3.1 20.5±3.3 -5.3 0.34 
Abdominal VAT (L) 5.8±0.6 5.7±0.5 0.1 4.3±0.4 4.2±0.4 -0.1 0.82 
Abdominal SAT (L)  8.2±0.7 7.7±0.7 -0.5 8.2±0.8 8.9±0.9  0.1 0.07 
Liver Enzymes 
ALT (u/L)  58±9 40±5 -22.6 85±17 64±11 -11.5 0.17 
AST (u/L)  37±5 29±2 -10.9 54±9 44±5      -2.2 0.19 
GGT (u/L)  74±23 55±15 -22.7 91±14 68±13 -20.3 0.78 
Glucose and Lipid Profile 
Fasting Glucose (mmol.L-1)  5.0±0.2 4.8±0.1   -0.3* 5.4±0.3 5.5±0.3    0.5* 0.008 
Cholesterol (mmol.L-1) 5.4±0.3 5.3±0.2 -0.1 5.4±0.3 5.3±0.4 -0.1 0.86 
Triglyceride (mmol.L-1)  2.0±0.2 1.9±0.1 -0.1 3.0±0.7 2.1±0.4 -0.5 0.22 
HDL (mmol.L-1) 1.3±0.1 1.4±0.1 0.03 1.2±0.1 1.2±0.0 -0.03 0.27 
LDL (mmol.L-1) 3.2±0.2 3.1±0.2 -0.1 2.8±0.2 3.3±0.3 0.2 0.22 
Chol:HDL ratio 4.1±0.3 4.0±0.3 -0.1 4.7±0.3 4.6±0.4 -0.1 0.92 
Cardiorespiratory Capacity VO2peak (ml.kg
-1.min-1)  26.4±2.1 33.4±2.7   7.0* 27.5±3.7 25.0±2.6   -2.3* 0.002 
 
Brachial Artery Vascular 
Function 
Flow-Mediated Dilation (%)  4.8±0.6 8.6±0.7   3.6* 5.5±0.8 5.5±0.5   0.3* 0.004 
Baseline Diameter (mm) 3.8±0.3 3.9±0.2 0.1 3.8±0.3 4.0±0.2 0.2 0.92 
Peak Diameter (mm) 4.1±0.4 4.3±0.3 0.2 4.0±0.3 4.2±0.1 0.1 0.79 
Shear rateAUC (s-1×103) 18.4±4.0 15.0±2.3 -27.0 11.5±1.8 13.8±3.1 -9.8 0.65 
Time to Peak (s) 68.0±11.0 52.6±7.4 -11.1 52.2±10.5 40.2±8.2  -20.2 0.46 
GTN-Mediated Dilation (%) 17.1±2.5 15.9±1.5 -0.9 15.9±2.3 15.8±2.6 -0.6 0.91 
Ex- Exercise group, CC- Conventional care group, SAT- Subcutaneous adipose tissue, VO2peak- Peak oxygen uptake. Data are presented as mean ± SE. 
Delta (Δ) change from pre-intervention following adjustment for pre-intervention values. * Significant difference between ΔEx and ΔCC (P<0.05).  
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5.3.2 Vascular measurements 
The change in FMD was significantly greater following supervised exercise training 
when compared with conventional clinical care (3.6±0.6 vs. 0.3±0.8%, P=0.004; Figure 
5.2). There was no significant difference in baseline or peak arterial diameter, shear rate 
or time to peak between interventions (Table 5.1).  
 
 
 
 
 
Figure 5.2 Individual delta change scores for FMD (%) following supervised exercise 
training and conventional care (black markers) and mean delta change following 
adjustment for pre-intervention data (red markers). According to published prognostic 
data by Inaba et al.,(2010) these data indicate that supervised exercise training may 
have reduced the risk of a future cardiovascular event by ~21%, whereas conventional 
care has a negligible impact on the future risk of cardiovascular events in NAFLD 
patients. 
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5.3.3 Biochemical characteristics 
Fasting plasma glucose reduced by 0.3±0.1mmol.L-1 following exercise training, but, 
increased by 0.5±0.2mmol.L-1 following conventional care (P=0.008; Table 5.1). There 
was no significant difference in serum liver enzymes, total, high-density lipoprotein or 
low-density lipoprotein cholesterol, HDL: cholesterol ratio or triglyceride concentration 
between interventions (P>0.05; Table 5.1).  
 
5.3.4 Hepatic and abdominal fat deposition 
There was no significant difference between the effect of exercise and conventional care 
on IHTC (P>0.05; Figure 5.3).  Abdominal SAT reduced by 0.5±0.1L following 
exercise training and increased by 0.1±0.2L following conventional care (P=0.07). 
There was no significant difference in weight, waist circumference, abdominal VAT or 
BMI between interventions (Table 5.1). 
 
 
Figure 5.3 Individual delta change scores for IHTC (%) following supervised exercise 
training and conventional care (black markers) and mean delta change following 
adjustment for pre-intervention data (red markers). 
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5.3.5 Change score correlations 
The increase in FMD following exercise training was not correlated with changes in 
cardiorespiratory fitness (r=-0.02, P=0.96), abdominal SAT (r=-0.01, P=0.81) or fasting 
plasma glucose (r=-0.003, P=0.99). There was a moderate inverse correlation between 
the change in FMD following conventional care and the change in cardiorespiratory 
fitness (r=-0.68, P=0.18) and fasting plasma glucose (r=-0.59, P=0.22), but neither of 
these correlations reached statistical significance. There was no correlation between the 
change in FMD and the change in abdominal SAT (r=0.26, P=0.74) following 
conventional care. 
 
5.4 Discussion 
The aim of the present study was to compare the effect of a supervised moderate 
intensity exercise training intervention with conventional clinical care on endothelial 
function in NAFLD patients.  The major finding was that supervised exercise training 
induced a greater increase in brachial artery FMD when compared with conventional 
care. These improvements were independent of reductions in IHTC and abdominal 
VAT. These data suggest that supervised exercise training is an effective management 
strategy, capable of improving endothelial function in NAFLD patients and hence the 
prevalence of heart disease and stroke in these high risk patients. 
 
This is the first study to examine the effect of exercise training on endothelial function 
in NAFLD. Previous studies in these patients have shown exercise training to have a 
therapeutic effect on traditional CVD risk factors such as waist circumference (Baba et 
al., 2006) and insulin resistance (van der Heijden et al., 2010). Nevertheless, endothelial 
dysfunction is regarded as the earliest manifestation of atherosclerotic disease, which is 
evident prior to overt clinical manifestations of disease. Furthermore, endothelial 
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function is a strong and independent prognostic marker of future cardiovascular events 
(Green et al., 2011a). Indeed, supervised exercise training mediated a mean 
improvement in FMD of 3.6% in NAFLD patients, which according to the prognostic 
data recently published by Inaba and colleagues (2010) is clinically relevant as this may 
subsequently reduce the risk of a cardiovascular event by ~21% in these high risk 
patients. Consequently, this study illustrates that regular exercise has a cardioprotective 
impact on the vasculature of NAFLD patients, which is superior to that of current 
conventional care in the UK. This exercise-mediated reduction in CVD risk is of 
particular clinical importance given that CVD is the leading cause of mortality in 
NAFLD patients, exceeding that of liver disease (Ong et al., 2008).  
 
Providing the most up-to-date guidelines for the measurement of FMD are utilised 
(Thijssen et al., 2011), it is accepted that the FMD response in conduit vessels such as 
the brachial artery is largely dependent on endothelial release of nitric oxide (NO) 
(Green et al., 2011a). Chapter 4 of this thesis along with other previous research 
(Villanova et al., 2005) has demonstrated that NAFLD patients exhibit impaired FMD 
and thus express a reduced production of the anti-atherogenic molecule, NO. The 
observation that exercise training enhanced FMD in the present study, although novel in 
NAFLD subjects, is in keeping with previous research that demonstrates exercise 
training improves NO-mediated endothelial function in comparable diseased 
populations such as type 2 diabetes (Maiorana et al., 2001), hypercholesterolaemia 
(Walsh et al., 2003) and metabolic syndrome (Lavrencic et al., 2000). Although 
exercise training is associated with improvements in traditional cardiovascular risk 
factors, these are typically quite modest in magnitude and unlikely to fully explain the 
benefits of exercise in terms of cardiovascular risk reduction (Green et al., 2008; Joyner 
& Green, 2009).  Regular exercise training has been shown to promote an increase in 
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NO bioavailability by reducing the number of oxygen free radicals and up-regulating 
endothelial NO synthase protein (Green et al., 2004a; Green et al., 2008) and these 
effects may be independent of improvement in risk factors (Green et al., 2003). 
Increased NO bioavailability is thought to be caused by direct impacts of recurrent 
shear stress as a result of repeated exercise bouts (Green et al., 2010). Consequently, 
these chronic benefits observed in NAFLD patients are indicative of an increase in NO 
production, which enhances vasomotor function and also decreases the risk of 
atherosclerotic development.  
 
Despite a significant increase in endothelium dependent FMD with exercise training, no 
difference in brachial artery endothelial independent vasodilatation in response to 
sublingual GTN administration were observed following the respective interventions. 
This finding is broadly consistent with those of previous studies investigating similar 
metabolic diseases (Maiorana et al., 2001), and further suggests that the exercise-
mediated changes in endothelial function are due to an increase in NO production rather 
than an increase in sensitivity of vascular smooth muscle. Moreover, exercise training 
did not induce any change in baseline brachial artery diameter, suggesting that, if 
structural changes in the arterial wall occurred as a result of exercise, they were not 
apparent at rest. This is also in keeping with previous research (Green et al., 2011b). 
 
Somewhat surprisingly, the differences in FMD we observed were not accompanied by 
significant changes in IHTC or abdominal VAT. Several previous studies have 
demonstrated moderate intensity exercise can significantly reduce IHTC in NAFLD 
patients (Bonekamp et al., 2008; Johnson et al., 2009; van der Heijden et al., 2010), 
However, this is the first study to compare an exercise intervention to conventional care 
of weight loss and increased physical activity. The current data clearly indicates that 
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supervised exercise training reduces IHTC, yet the conventional care group also 
reduced IHTC, albeit to a lesser degree. Intriguingly, a difference in fasting glucose was 
evident post intervention, with a reduction in glucose observed following exercise but 
an increase in glucose following conventional care. Although this data is limited to the 
measurement of plasma glucose alone, this could indicate that despite a modest 
reduction in IHTC, conventional care does not aid in glucose control. Given that 
NAFLD is a pre-diabetic condition, this finding implies that exercise-induced 
improvements in cardiorespiratory fitness are necessary for effective maintenance of 
glycaemic control in patients at high risk of type 2 diabetes. This is corroborated by the 
findings of the Diabetes Prevention Program Research Group (2002), which 
demonstrated that a lifestyle intervention consisting of increased physical activity and 
weight loss is more effective than metformin in reducing the incidence of type 2 
diabetes. Specifically, lifestyle intervention induced a 58% reduction, whereas 
metformin only elicited a 31% reduced incidence of type 2 diabetes. 
 
Another noteworthy observation was that neither intervention caused significant 
reductions in abdominal VAT despite a trend for a reduction in abdominal SAT. This is 
in contrast to one previous study which observed a 12% relative reduction in abdominal 
VAT as well as a 21% relative reduction in IHTC in NAFLD patients following four 
weeks of high intensity cycle ergometer exercise training (Johnson et al., 2009). It is 
probable that a higher intensity exercise training intervention may have mediated 
greater reductions in both IHTC and abdominal VAT in the present study. Nonetheless, 
improvements in endothelial function following supervised exercise training in the 
current study were independent of concomitant changes in fat levels, implying that 
exercise has a direct therapeutic impact on endothelial function in NAFLD. 
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In summary, these novel findings suggest that supervised exercise training is an 
effective management strategy capable of improving endothelial function in NAFLD 
patients. Improvements in endothelial function occurred without significant reductions 
in IHTC or abdominal VAT and were not mediated by improvements in 
cardiorespiratory fitness or glycaemic control. Consequently, these data indicate that 
exercise has an independent and direct therapeutic impact on endothelial function in 
NAFLD, which may decrease the risk of heart disease and stroke in these high risk 
patients. Thus, exercise prescription should be recommended as a cardioprotective 
management strategy in NAFLD. 
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Chapter 6 
ENDOTHELIAL FUNCTION IN NAFLD PATIENTS 
12 MONTHS FOLLOWING THE CESSATION OF 
SUPERVISED EXERCISE TRAINING 
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6.1 Introduction 
Prevention of highly prevalent diseases such as type 2 diabetes and cardiovascular 
disease (CVD) is a major public health challenge. In the UK alone, 2.9 million people 
(4.9% of the population) are affected by diabetes (Shaw et al., 2010). Furthermore, 2.7 
million people are living with CVD and alarmingly, CVD is the main cause of mortality 
in the UK accounting for approximately 191,000 deaths each year (Allender et al., 
2011).  Non-alcoholic fatty liver disease (NAFLD), a recently identified phenomenon, 
which is related to obesity, confers an independent risk of insulin resistance, type 2 
diabetes and CVD (Stefan et al., 2008). Epidemiological research indicates that CVD 
accounts for a greater number of deaths than that of liver disease in NAFLD patients 
(Ekstedt et al., 2006; Ong et al., 2008; Soderberg et al., 2010) and some report CVD to 
be the leading cause of mortality (Ekstedt et al., 2006; Ong et al., 2008).  
 
Obesity and type 2 diabetes are now extremely common in Westernised societies and 
NAFLD is also becoming increasingly prevalent (20-30% of general population, ~70-
90% of obese and type 2 diabetic individuals (Adams & Angulo, 2005; Marchesini et 
al., 2005; Neuschwander-Tetri, 2005). Therefore, effective and sustainable 
interventions to reduce hepatic fat and the risk of type 2 diabetes and CVD are vital. 
Currently, there are no recommended pharmacological treatments to reduce hepatic fat 
therefore current clinical guidelines recommend lifestyle interventions comprising of 
physical activity and diet. Critically, Chapter 5 demonstrated for the first time that 
supervised exercise training improves endothelial function, an early marker in the 
development of atherosclerosis and predictor of future cardiovascular events, in 
NAFLD patients. Moreover, exercise training also provoked a 9% absolute reduction in 
intrahepatocellular triglyceride content (IHTC), a finding that is corroborated by several 
research groups (Bonekamp et al., 2008; Johnson et al., 2009; van der Heijden et al., 
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2010). Importantly, these beneficial effects were evident over and above that of general 
lifestyle advice, provided as part of clinical care, suggesting that supervised exercise 
training is an effective non-pharmacological management strategy. 
 
Lifestyle modification is difficult to maintain without supervision, yet, for exercise 
training to be endorsed as a credible therapeutic intervention to reduce the risk of type 2 
diabetes and CVD, it is essential that the beneficial effects are evident long-term. For 
example, the diabetes prevention program research group (Knowler et al., 2009) 
conducted a 10-year follow up study in type 2 diabetic patients. The authors reported a 
diminished incidence of type 2 diabetes following a lifestyle intervention compared 
with metformin and placebo interventions, indicative that lifestyle intervention, in the 
form of exercise and weight loss, delayed or even prevented the onset of diabetes. 
Therefore, the aim of the present study was to investigate whether exercise-induced 
improvements in endothelial function in NAFLD patients are sustained 12-months 
following the cessation of supervised exercise training. It was hypothesised that 
exercise-induced improvements in endothelial function in NAFLD patients would 
abolish 12-months following the cessation of supervised exercise training. 
  
6.2 Methods 
6.2.1 Participants 
Nine NAFLD patients (5 males, 4 females, 50±5yrs, BMI 30±1kg/m2) were recruited. 
All NAFLD patients were normocholesterolaemic; one participant was hypertensive 
and was treated with a β-blocker. Medications were not altered during the course of the 
study. All female participants were post-menopausal, except one, who had undergone a 
hysterectomy. 
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6.2.2 Research Design 
Physiological measurements were performed in all NAFLD patients at baseline, 
following a 16-week supervised moderate intensity exercise training program and 12-
months following the completion of the exercise training program. 
 
6.2.3 Experimental Protocol 
Participants reported to the laboratory to undertake a number of physiological 
examinations, which included anthropometric assessments, a blood sample, assessment 
of brachial artery function, a cardiorespiratory fitness test and proton magnetic 
resonance spectroscopy (1H-MRS) to determine intrahepatocellular triglyceride content 
(IHTC) (for details of measurement procedures, please refer to General Methodology; 
Chapter 3). Measurements were performed following an overnight fast, 12-hour 
abstinence from caffeine and 24-hour abstinence from alcohol and strenuous exercise.  
 
6.2.4 Statistical Analysis 
A within subjects repeated measures analysis of variance (ANOVA) was used to 
evaluate differences between baseline data, post training data and 12-months post 
training data. Data were analyzed using the SPSS 17.0 (SPSS, Chicago, Illinois) 
software. Data are presented in the text as mean±SE and exact P values are cited (values 
of P of “0.000” provided by the statistics package are reported as “<0.0005”). 
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6.3 Results 
6.3.1 Cardiorespiratory Fitness 
There was a significant difference in cardiorespiratory fitness across the three time 
points (P=0.004; Figure 6.1). Specifically, peak oxygen uptake increased from 
26.4±2.3ml.kg-1.min-1 at baseline to 33.0±3.5ml.kg-1.min-1 following supervised exercise 
training (P=0.009). Additionally, peak oxygen uptake reduced (33.0±3.5 vs. 
26.7±2.8ml.kg-1.min-1) 12 months following the completion of exercise training 
(P=0.004). There was no difference between cardiorespiratory fitness at baseline and 12 
months following the completion of supervised exercise training (26.4±2.3 vs. 
26.7±2.8ml.kg-1.min-1; P=0.86). 
 
 
Figure 6.1 Cardiorespiratory fitness of NAFLD patients at baseline, following 16-
weeks of structured and supervised exercise training (Post Exercise) and 12 months 
following (12-Month FU) the cessation of supervised exercise (P=0.004). 
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Table 6.1 Characteristics of NAFLD patients at baseline, following 16-weeks of 
structured and supervised exercise training (Post Exercise) and 12 months following 
(12-Month FU) the cessation of supervised exercise. 
 Baseline Post 
Exercise 
12-Month                                                                                 
FU 
P
value 
Anthropometrics 
  Weight (kg) 
 
85.0±4.3 
 
82.5±4.6 
 
84.5±6.5 
 
0.41 
  BMI (kg/m2) 30±1 29±1 30±1 0.38 
  Waist circumference (cm)  101.8±2.7 97.6±3.1 100.6±5.0 0.15 
  Systolic blood pressure (mmHg) 126±2 124±3 130±5 0.54 
  Diastolic blood pressure (mmHg) 78±2 78±2 78±4 0.89 
Liver Function     
  IHTC (%) 23.3±5.9 16.6±4.1 28.4±7.2 0.13 
  ALT (u/L)  54±12 36±6 † 65±13 ‡ 0.02 
  AST (u/L)  35±6 27±2 † 42±5 ‡ 0.01 
  GGT (u/L)  87±33 63±21† 71±15 0.05 
Glucose and Lipid Profile      
   Fasting Glucose (mmol.L-1)  5.0±0.2 4.8±0.2 5.1±0.2 0.38 
   Cholesterol (mmol.L-1) 5.3±0.4 5.3±0.3 5.7±0.3 0.12 
   Triglyceride (mmol.L-1)  2.0±0.2 1.9±0.2 2.0±0.2 0.87 
   HDL (mmol.L-1) 1.4±0.1 1.4±0.4 1.4±0.1 0.44 
   LDL (mmol.L-1) 3.0±0.3 3.0±0.3 3.2±0.3 0.33 
   Chol:HDL ratio  3.8±0.3 3.8±0.3 4.0±0.3 0.56 
Cardiorespiratory Capacity     
   VO2peak (ml.kg
-1.min-1)  26.4±2.3 33.0±3.5 † 26.7±2.8 ‡ 0.004 
Brachial Artery Vascular Function      
   Flow-Mediated Dilation (%)  5.1±0.8 7.9±0.8 † 5.0±0.5 ‡ 0.007 
   Baseline Diameter (mm) 4.0±0.3 4.0±0.3 4.2±0.3 0.36 
   Peak Diameter (mm) 4.2±0.4 4.4±0.3 4.4±0.3 0.48 
  Shear rateAUC (s
-1×103) 17.4±4.8 16.6±3.3 16.7±3.1 0.83 
   Time to Peak (s) 64.0±13.6 55.4±10.1 79.4±16.0 0.23 
   GTN-Mediated Dilation (%) 13.5±1.9 14.6±1.9 14.9±0.7 0.74 
† Significantly different from baseline data (P<0.05). 
‡ Significantly different from post exercise data (P<0.05). 
 
6.3.2 Vascular measurements 
There were significant changes in FMD across the three time points (P=0.007; Figure 
6.2). FMD improved from 5.1±0.8% to 7.9±0.8% in response to supervised exercise 
training (P=0.004) and reduced (5.0±0.5%) 12 months following the completion of 
supervision (P=0.02) to a similar level to that observed at baseline (5.1±0.8 vs. 
5.0±0.5%; P=0.95). There was no difference in GTN mediated dilation between the 
three time points (P=0.60; Table 6.1). In addition, there was no significant difference in 
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baseline or peak arterial diameter, shear rate or time to peak between assessments 
(P>0.05; Table 6.1).  
 
 
Figure 6.2 FMD in NAFLD patients at baseline, following 16-weeks of structured and 
supervised exercise training (Post Exercise) and 12 months following (12-Month FU) 
the cessation of supervised exercise (P=0.007). 
 
 
6.3.3 Biochemical characteristics 
Serum liver enzymes all differed across the three time points (P<0.05; Table 6.1). ALT 
(54±12 vs. 36±6u/L; P=0.01), AST (35±6 vs. 27±2u/L; P=0.06) and GGT (87±33 vs. 
63±21u/L; P=0.005) all decreased in response to supervised exercise training. Twelve 
months following the completion of supervised exercise, all serum liver enzymes 
increased to similar levels observed at baseline (P>0.05). Specifically, ALT increased 
from 36±6 to 65±13u/L (P=0.02), AST increased from 27±2 to 42±5u/L (P=0.01) and 
GGT increased from 63±21 to 71±15u/L (P=0.08). No significant changes in fasting 
glucose or blood lipid profiles were evident across the three time points (P>0.05; Table 
6.1). 
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6.3.4 Hepatic fat content 
No difference in IHTC was evident across the three time points (P=0.13; Figure 6.3). 
 
Figure 6.3 IHTC in NAFLD patients at baseline, following 16-weeks of structured and 
supervised exercise training (Post Exercise) and 12 months following (12-Month FU) 
the cessation of supervised exercise (P=0.13). 
 
 
6.4 Discussion 
The aim of the present study was to investigate whether exercise-induced improvements 
in endothelial function in NAFLD patients are sustained 12-months following the 
cessation of supervised exercise. The major finding was that exercise-induced 
improvements in brachial artery FMD were abolished 12-months following the 
cessation of supervised exercise. These data suggest that in order to chronically sustain 
the cardio-protective impact of supervised exercise training on the vasculature of 
NAFLD patients and subsequently reduce the risk of future cardiovascular events in this 
high risk group, long term exercise supervision and guidance is required. 
 
This is the first study to examine the effect of exercise training on endothelial function 
in NAFLD and to conduct a long term follow up assessment to establish whether the 
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exercise-induce improvements are sustained. Following 16-weeks of supervised 
moderate intensity exercise training FMD increased by 2.8% in NAFLD patients, 
however, this improvement was abolished 12-months following the cessation of 
supervised exercise. Endothelial dysfunction is characterised by a diminished FMD 
response and is regarded as the earliest manifestation of atherosclerotic disease, which 
is evident prior to overt clinical manifestations of CVD. Furthermore, FMD is a strong 
independent prognostic marker of future cardiovascular events (Green et al., 2011a). 
Therefore, these findings suggest that the cardio-protective benefit and consequential 
reduced risk of future cardiovascular events observed following supervised exercise 
training in NAFLD patients is eradicated 12-months after the cessation of supervised 
exercise. 
 
Although an exercise training follow-up study of this nature on endothelial function has 
not been previously conducted in any population, Vona et al. (2009) demonstrated that 
exercise-induced improvements in endothelial function are abolished after one month of 
detraining in CVD patients. This finding elegantly demonstrated that improvements in 
endothelial function are not chronically sustained following cessation of exercise. The 
reduction in cardiorespiratory fitness observed 12 month post-intervention suggests that 
this patient group did not successfully maintain the exercise training regimen and/or did 
not achieve the optimal exercise dose required to sustain cardiovascular benefits 
without guided supervision. It is clear from the current data that in order for exercise to 
induce a sustained therapeutic benefit in NAFLD patients, guided supervision is 
essential. 
 
Unlike several previous studies (Bonekamp et al., 2008; Johnson et al., 2009; van der 
Heijden et al., 2010), a statistically significant reduction in IHTC following exercise 
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training was not observed in the current study. However, it is important to note that the 
exercise-induced absolute reduction in IHTC of 9% was clinically relevant and, that this 
improvement was abolished 12-months following cessation of supervised exercise 
training. Indeed, this trend is supported by the serum liver enzymes data, which 
demonstrate a significant reduction following exercise that is abolished 12-months after 
the cessation of supervised exercise. Moreover, this data also supports the notion that 
supervised exercise is crucial in order to promote sustained long term improvements to 
cardiovascular and metabolic health in NAFLD patients. 
 
In summary, these novel findings suggest that whilst supervised exercise training is an 
acute non-pharmacological management strategy capable of improving endothelial 
function in NAFLD, the cardio-protective impact of supervised exercise training is not 
chronically sustained following the cessation of supervised exercise. In order to sustain 
the exercise-induced improvements in the endothelial function of NAFLD patients and 
subsequently reduce the prevalence of heart disease and stroke in this high risk group, 
long term exercise supervision and guidance is required.  
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Chapter 7 
THE IMPACT OF NAFLD ON NITRIC OXIDE 
MEDIATED CUTANEOUS MICROVASCULAR 
FUNCTION AND THE EFFECTS OF SUPERVISED 
EXERCISE TRAINING COMPARED WITH 
CONVENTIONAL CLINICAL CARE 
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7.1 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is primarily a hepatic disorder, characterised 
by excess triglyceride accumulation in the liver and is associated with an increased risk 
of cardiovascular disease (CVD) (Stefan et al., 2008). Endothelial dysfunction is an 
early and integral event in CVD and a strong predictor of future cardiovascular risk in 
both symptomatic and asymptomatic individuals (Green et al., 2011a). Recent cross 
sectional studies have shown that NAFLD patients exhibit impaired endothelial function 
in conduit arteries (Villanova et al., 2005; Senturk et al., 2008). In addition, Chapter 5 
illustrated that a structured exercise intervention improves conduit artery endothelial 
function in this group who are at high risk of cardiovascular events (Targher et al., 
2010), suggesting that exercise enhances cardiovascular health in NAFLD patients.  
 
Whilst conduit artery endothelial function reflects macrovascular atherosclerotic risk, 
cutaneous vasodilator function reflects generalised microvascular function and provides 
a translational model to investigate pre-clinical disease (Holowatz et al., 2008). 
Cutaneous microvessel dysfunction correlates with coronary artery endothelial 
dysfunction (Shamim-Uzzaman et al., 2002; Bonetti et al., 2004; Khan et al., 2008) and 
several cardiovascular risk factors including obesity (de Jongh et al., 2004), 
hypertension (Carberry et al., 1992; Rizzoni et al., 2003), hypercholesterolaemia (Khan 
et al., 1999), and type 2 diabetes (Sokolnicki et al., 2007); all of which frequently 
manifest in NAFLD patients (Ekstedt et al., 2006) . Although, hepatic microvascular 
dysfunction is well documented in NAFLD (Ijaz et al., 2003), no previous research has 
investigated the cutaneous microcirculation as a model of preclinical microvascular 
disease in NAFLD patients.  
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Previous research has demonstrated that endothelium-derived nitric oxide (NO)-
mediated vasodilator function in cutaneous microvessels is related to age and fitness in 
healthy individuals and that exercise training enhances microvascular function by up-
regulating NO (Black et al., 2008b) in older subjects.  Nevertheless, research 
investigating the impact of exercise training on cutaneous NO-mediated microvascular 
function in diseased populations is scant. The aims of the present study were therefore 
to (i) describe the NO-mediated cutaneous vasodilator response to local heating in 
NAFLD, versus matched controls; and (ii) utilise a randomised controlled intervention 
to investigate NO-mediated cutaneous microvascular responses to supervised exercise 
training compared with conventional clinical care. It was hypothesised that (i) the NO-
mediated cutaneous vasodilator response to local heating would be impaired in NAFLD 
patients when compared with matched controls and (ii) supervised exercise training 
would induce a greater improvement in the NO-mediated cutaneous vasodilator 
response to local heating in NAFLD when compared with conventional clinical care. 
 
7.2 Methods 
7.2.1 Participants 
Thirteen sedentary NAFLD patients (7 males, 6 females, 50±3yrs, BMI 31±1kg/m2) and 
seven matched controls (3 males, 4 females, 48±4yrs, BMI 30±2 kg/m2) were recruited. 
All NAFLD patients were normocholesterolaemic and 3 were taking anti-hypertensive 
medication (β-blocker n=1, Calcium channel blocker n=2). Medications were not 
altered during the course of the study. None of the controls were taking any prescribed 
medication. Pre-menopausal women (n=2) were tested during the early follicular phase 
of the menstrual cycle, defined as day 1-7. 
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7.2.2 Research Design 
A series of physiological measurements were performed at baseline in all participants. 
Following this, all NAFLD patients were randomly assigned to either 16-weeks of 
supervised and structured exercise training (n=6, 45±5yrs, BMI 31±1kg/m2) or to 16-
weeks of conventional care (n=5, 51±3yrs, BMI 30±2kg/m2) (for details of respective 
interventions, please refer to General Methodology, Chapter 3). Eleven NAFLD 
patients completed the 16-week intervention period, following which baseline 
measurements were repeated (Figure 7.1).  
 
 
Figure 7.1 Participant flow diagram 
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7.2.3 Experimental Protocol 
All participants reported to the laboratory to undertake a series of baseline 
measurements including anthropometric assessment, a blood sample, an assessment of 
cutaneous NO vasodilator function, a cardiorespiratory fitness test and magnetic 
resonance imaging (MRI) with proton magnetic resonance spectroscopy (1H-MRS) to 
determine abdominal fat deposition and intrahepatocellular triglyceride content (IHTC). 
All participants were studied at the same time of day to control for the impact of 
circadian variation. Measurements were performed following an overnight fast, 12-hour 
abstinence from caffeine and 24-hour abstinence from alcohol and strenuous exercise.  
 
7.2.4 Assessment of cutaneous NO vasodilator function  
7.2.4.1 Microdialysis fibre instrumentation 
All intradermal microdialysis assessments were performed in a quiet, temperature 
controlled laboratory. Upon arrival, participants were instrumented and cannulation for 
microdialysis probe insertion was undertaken (~15-min). Once seated comfortably in a 
custom-designed bed, the right arm was supinated and supported for insertion of 
microdialysis fibres. The insertion sites were marked on the skin and cold packs were 
applied as a form of local anaesthesia. Two 21-gauge needles were inserted ~5cm apart 
from one another and ~0.3-1.0mm beneath the epidermal surface so to enable threading 
and placement of two microdialysis fibres (Linear 30, CMA Microdialysis Ltd,  
Stockholm, Sweden), containing 10mm long 6 kDa membranes. The needles were then 
removed and the embedded fibres were perfused with saline solution at a rate of 5 
µl.min-1 using a microinfusion pump (Model 11 plus, Harvard Apparatus, MA, USA) 
(Figure 7.2).  
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Figure 7.2 The microdialysis fibre is placed ~0.3-1.0mm beneath the epidermal surface 
so that it is positioned within the dermal space. The 10mm semi-permeable membrane 
allows infusion of agonists directly into the vascular bed to be investigated. A laser 
Doppler probe is positioned above it to monitor skin blood flow (SKBF) (Cracowski et 
al., 2006). 
 
Following this, integrated laser Doppler probes (Model 413, Periflux 5001 System, 
Perimed AB, Sweden) combined with local heating disks (Perimed 455, Stockholm, 
Sweden) set at 33°C were placed above both embedded microdialysis fibres (Figure 
7.2). Laser Doppler flowmetry uses a laser diode to emit a monochrome light at a 
penetrative depth of approximately 1mm3. The incident monochrome light reflects off 
moving blood cells causing a shift in the returning wavelength (Doppler effect) from 
which estimates of cutaneous blood flux (the concentration of red blood cells x their 
velocity) can be made. Consequently, LDF enables sensitive and quantifiable detection 
of relative changes in skin blood flow (SKBF) in response to a given stimulus.  
 
7.2.4.2 Physiological NO-mediated vasodilatation 
Following a ~90-min equilibration period, the skin surrounding both microdialysis 
probes was gradually heated, using local heating disks, from 33 to 42°C at a rate of 
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0.5 °C per 2.5-min (45-min). Thereafter, both sites were continuously heated at 42°C 
for a further 30-min. This gradual heating protocol was used to minimise the impact of 
heating on axon reflexes, which are less NO-mediated than slow heating component 
responses (Minson et al., 2001; Houghton et al., 2006). Saline solution was infused 
throughout the protocol in one probe and L-NG-monomethyl arginine (L-NMMA; 
10mM, 5 μl min−1, Clinalfa, CalBiochem) infused through the second probe, from 30-
min prior to the onset of heating. Sodium nitroprusside (SNP, 56mM, Mayne Pharma, 
Warwickshire, UK), a potent NO donor, was infused at the end of the protocol for 30-
min (Minson et al., 2002; Cracowski et al., 2006) to initiate peak vasodilatation (Figure 
7.3). 
 
Figure 7.3 Schematic of the physiological (localised heating) NO-mediated 
vasodilatation protocol. 
 
7.2.4.3 Assessment of forearm skin blood flow 
To obtain an index of SKBF, cutaneous red cell flux was measured by placing 
integrated laser-Doppler probes, each consisting of a seven-laser array, above each 
microdialysis fibre. The laser-Doppler probe signals were continuously monitored via 
an online software chart recorder (PSW, Perimed, Sweden). At each designated study 
time point (2.5 minute intervals), SKBF was assessed by averaging laser-Doppler flux 
(LDf), measured in perfusion units (PU), over a stable 30-second period. These data 
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were subsequently converted to cutaneous vascular conductance (CVC), calculated as 
LDf/MAP (PU mmHg−1), where MAP was derived from contemporaneous automated 
blood pressure measures (Dinamap; GE Pro 300V2) in the contralateral arm. Values 
were then expressed relative to the maximal CVC achieved during infusion of 56mM 
SNP at 42 °C, as %CVCmax, the preferred method of data expression adopted in the 
literature (Cracowski et al., 2006). 
 
7.2.4.4 Data Reduction 
Data during the incremental heating were calculated and presented at each temperature 
(every 0.5°C from 33°C to 42°C) for both the saline and L-NMMA microdilaysis sites. 
The contribution of NO was calculated by subtracting individual L-NMMA data from 
saline data collected contemporaneously. Data are therefore presented as the NO 
contribution to microvascular red cell flux or SKBF. Summary data were calculated for 
resting SKBF (measured at 33°C following trauma cessation of ~90 min); Peak SKBF 
(measured at 42°C following the incremental heating protocol); and Prolonged SKBF 
(measured following 30 min of continuous heating at 42°C).  
 
7.2.5 Statistical Analysis 
All differences in baseline characteristics between groups (NAFLD and controls) were 
compared using independent t-tests. Data that was not normally distributed was 
logarithmically transformed. Data are presented in the text as mean±SE and exact P 
values are cited (values of P of “0.000” provided by the statistics package are reported 
as “<0.0005”). All data were analysed using the SPSS 17.0 (SPSS, Chicago, Illinois) 
software. 
 
107 
 
Cross-sectional comparison between NAFLD patients and matched controls: To ensure 
successful increase in NO production with the local heat stimulus and successful 
blockade of NO production, saline and L-NMMA data were individually compared 
using a two-way repeated measures analysis of variance (ANOVA) (site vs. 
temperature). For the comparison of NAFLD versus controls the incremental heating 
data was analysed using a two-way factor (group vs. temperature) repeated measures 
ANOVA. Statistically significant interactions between these two factors were followed-
up with subsequent pairwise comparisons. The summary data for the comparison 
between NAFLD and controls was analysed using a between groups ANOVA. 
 
Effect of exercise training vs. conventional care: A two-way repeated measures 
ANOVA (site vs. temperature), as described above, was employed to ensure successful 
increase in NO production and blockade respectively. For the comparison of the 
exercise versus the conventional care intervention delta (Δ) change from pre-
intervention was calculated and analysed using analysis of covariance (ANCOVA) with 
pre-exercise data as a covariate. Similarly, the summary data for the effect of exercise 
versus conventional care data was analysed using ANCOVA with pre-exercise data as a 
covariate. 
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7.3 Results 
7.3.1 Cross-sectional comparison between NAFLD and matched controls 
NAFLD patients and controls were well matched for age, BMI and fitness, however, 
NAFLD patients exhibited an increased waist circumference (106±2 vs. 99±2cm; 
P=0.05; Table 7.1).  There was a ~7 fold greater deposition of IHTC (P=0.0004) in 
NAFLD patients and a suggestion of increased abdominal VAT (P=0.05). Serum liver 
enzymes were elevated in NAFLD patients (P<0.01) and HDL reduced (1.3±0.1 vs. 
1.5±0.1mmol.L-1; P=0.05) when compared with controls. 
 
Table 7.1 Baseline characteristics of NAFLD and control participants. 
 NAFLD Controls P Value 
Anthropometrics    
  N (m/f) 13 7 N/A 
  Age (yrs) + 48(13) 48(15) 0.60 
  Weight (kg) 88.6±3.5 84.4±4.0 0.46 
  BMI (kg/m2) 31±1 30±2 0.64 
  Waist circumference (cm)  106±2 99±2   0.05* 
  Systolic blood pressure (mmHg) 128±3 128±4 0.98 
  Diastolic blood pressure (mmHg) 78±2 80±3 0.54 
Hepatic and Body Fat Deposition    
  IHTC (%)++ 28.8±5.3 3.2±0.7     0.0004* 
  Abdominal VAT (l) 4.8±0.4 3.8±0.7   0.05* 
  Abdominal SAT (l) ++ 8.9±0.8 8.5±1.4 0.81 
Liver Enzymes    
  ALT (u/L) ++ 72±12 29±5 0.002* 
  AST (u/L) ++ 44±6 25±3 0.02* 
  GGT (u/L)  75±11 32±6 0.01* 
Glucose and Lipid Profile    
   Fasting Glucose (mmol.L-1)  5.0(0.9) 4.9(0.8) 0.60 
   Cholesterol (mmol.L-1) 5.6±0.2 5.3±0.3 0.36 
   Triglyceride (mmol.L-1) 2.5±0.4 1.7±0.3 0.23 
   HDL (mmol.L-1) 1.3±0.1 1.5±0.1   0.05* 
   LDL (mmol.L-1) 3.3±0.2 3.6±0.6 0.53 
   Chol:HDL ratio + 5.0(1.0) 4.0(1.0) 0.10 
Cardiorespiratory Capacity    
   VO2Peak (ml/kg
-1/min-1) + 22.8(15.4) 27.8(19.2) 0.22 
SAT- Subcutaneous adipose tissue, VO2peak- Peak oxygen uptake
  
+ Non-parametric data presented as median (interquartile range). 
++ Logarithmically transformed data.  
* Significant difference between NAFLD vs. controls (P<0.05). 
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7.3.2 Incremental Heating 
In response to local heating, %CVCmax steadily and significantly increased at the 
microdialysis site perfused with saline and the site perfused with L-NMMA in all 
participants (P<0.0005) (Figure 7.4). However, at the L-NMMA site %CVCmax was 
significantly decreased in both NAFLD patients and controls (P<0.0005; Figure 7.4), 
suggesting that the response to local heating is partially mediated by the NO dilator 
system in both groups. A significant microdialysis site x temperature interaction was 
evident (P<0.001, Figure 7.4); Pairwise comparisons revealed significant differences 
between the saline and L-NMMA site from 39.5-42ºC and subsequently when the 
heating stimulus remained at 42°C for 5 minutes (peak) in NAFLD patients and from 
40-42ºC and at peak SKBF in controls (P<0.05). 
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Figure 7.4 The effect of incremental and prolonged heating on SKBF in the saline and 
L-NMMA microdialysis sites in NAFLD patients (A) and matched controls (B). 
0 min-peak SKBF, 30 min-prolonged SKBF. 
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7.3.3 Nitric Oxide contribution to incremental heating  
There was no significant interaction between NAFLD and controls in the saline or L-
NMMA microdialysis sites (P>0.13), and similarly, NO contribution (saline %CVCmax 
minus L-NMMA %CVCmax) did not differ between NAFLD and controls (P=0.47; 
Figure 7.5).  
 
 
Figure 7.5 The effect of incremental and prolonged heating on the contribution of NO 
(saline %CVCmax minus L-NMMA %CVCmax) in NAFLD patients and matched 
controls. 0 min-peak SKBF, 30 min-prolonged SKBF. 
 
When the data is expressed in summary fashion, it remains evident that there were no 
significant differences in the contribution of NO to resting, peak or prolonged SKBF in 
NAFLD patients compared to controls (P>0.05; Figure 7.6), and that the % contribution 
of NO to peak vasodilatory response was similar between groups at ~30%.  
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Figure 7.6 Mean NO contribution (saline %CVCmax minus L-NMMA %CVCmax) to 
resting, peak (42°C) and prolonged (30 mins at 42°C) SKBF in the NAFLD and 
matched controls.  
 
 
7.3.4 The effect of supervised exercise training vs. conventional care 
The characteristics of all NAFLD patients allocated to each group are presented in 
Table 7.2. NAFLD patients who were randomised to supervised exercise training 
demonstrated 94% compliance to exercise sessions. Following the intervention, 
cardiorespiratory fitness (10.1±2.2 vs. -0.9±2.5; P=0.01) improved and ALT (-34±6 vs. 
-12±7; P=0.04) and AST (-16±2 vs. -4±3; P=0.01) reduced in the exercise-trained 
group compared to the conventional care group. However, there was no difference 
between the effect of exercise training and conventional care on BMI, waist 
circumference, IHTC, abdominal VAT, plasma lipid profile or plasma glucose 
concentration. 
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Table 7.2 Changes in the characteristics of NAFLD patients following supervised exercise training (n=6) and conventional clinical care (n=5). 
 Pre Ex Post Ex ∆ Ex Pre CC Post CC ∆ CC P value 
Anthropometrics        
Weight (kg) 92.9±4.4 90.8±4.5 -2.3±0.9 84.1±7.4 83.2±7.9 -0.7±0.9 0.27 
BMI (kg/m2) 31±1 30±1 -0.8±0.3 30±2 30±2 -0.8±0.4 0.98 
Waist circumference (cm)  109±3 103±3 -5.5±2.5 104±4 101±4 -3.4±2.7 0.61 
Systolic blood pressure (mmHg) 132±2 127±3 2±4 124±7 122±5 -3±4 0.43 
Diastolic blood pressure (mmHg) 81±2 78±2 -2±2 75±4 72±1 -6±2 0.11 
Body Fat Deposition        
IHTC (%) 34.4±11.0 18.7±4.7 -13.0±3.0 24.4±4.6 20.5±4.7 -6.5±3.3 0.18 
Abdominal VAT (L) 5.8±0.6 5.4±0.8 -0.5±0.3 4.0±0.5 4.2±0.4 0.3±0.4 0.09 
Abdominal SAT (L)  9.2±1.3 8.9±1.4 -0.4±0.3 8.2±0.9 8.4±1.1 0.2±0.4 0.25 
Liver Enzymes        
ALT (u/L)  67±16 36±4 -34±6* 80±23 64±16 -12±7* 0.04 
AST (u/L)  42±10 29±3 -16±2* 50±11 44±6 -4±3* 0.01 
GGT (u/L)  59±11 41±6 -29±11 109±13 80±16 -16±12 0.51 
Glucose and Lipid Profile        
Fasting Glucose (mmol.L-1)  4.9±0.1 4.9±0.2 -0.1±0.2 5.5±0.5 5.7±0.4 0.3±0.2 0.25 
Cholesterol (mmol.L-1) 5.5±0.3 5.2±0.3 -0.3±0.2 5.7±0.3 5.6±0.5 -0.1±0.2 0.51 
Triglyceride (mmol.L-1)  2.0±0.2 1.8±0.2 -0.6±0.2 3.5±0.9 2.5±0.4 -0.6±0.2 0.81 
HDL (mmol.L-1) 1.3±0.1 1.3±0.1 0.03±0.04 1.2±0.1 1.2±0.1 -0.04±0.04 0.26 
LDL (mmol.L-1) 3.3±0.3 3.1±0.2 -0.1±0.1 2.8±0.3 3.5±0.4 0.3±0.2 0.10 
Chol:HDL ratio 4.2±0.2 3.8±0.2 -0.6±0.3 5.0±0.3 5.0±0.3 0.3±0.3 0.09 
Cardiorespiratory Capacity        
VO2peak (ml.kg-1.min-1)  26.8±3.2 36.5±3.6 10.1±2.2* 22.4±1.1 25.0±2.6 -0.9±2.5* 0.01 
Ex- Exercise group, CC- Conventional care group, SAT- Subcutaneous adipose tissue, VO2peak- Peak oxygen uptake. Data are presented as mean ± SE. 
Delta (Δ) change from pre-intervention following adjustment for pre-intervention values. * Significant difference between ΔEx and ΔCC (P<0.05).
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7.3.5 Post Intervention response to incremental heating  
Pre and post-exercise training, SKBF significantly increased in response to local heating 
at both the saline and L-NMMA sites (P>0.0005; Figure 7.7). There was however, a 
significant interaction (site x temperature) between the saline and L-NMMA 
microdialysis sites both pre and post exercise training (P>0.0005; Figure 7.7), with 
significant differences between sites evident from 39-42oC pre-exercise and from 36.5-
42oC and at peak SKBF post-exercise. Similarly, there was a significant interaction (site 
x temperature) between the saline and L-NMMA microdialysis sites both pre and post 
conventional care (P>0.0005; Figure 7.8). Pairwise comparisons revealed differences 
from 39-42°C and at peak SKBF pre-conventional care and 40-42°C and at peak SKBF 
post-conventional care. 
 
7.3.6 Post intervention nitric oxide contribution to incremental heating  
When data is expressed as NO contribution to %CVCmax, there was a significant 
interaction (intervention vs. temperature) in NO contribution during incremental heating 
from 37.5°C to 42°C in the exercise trained group (P=0.01; Figure 7.9), but no 
interaction in the conventional care group (P=0.99; Figure 7.9).  
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Figure 7.7 The effect of incremental and prolonged heating on SKBF in the saline and 
L-NMMA microdialysis sites pre (A) and post exercise (B) *Significant difference 
between L-NMMA and saline sites (P<0.05). 0 min-peak SKBF, 30 min-prolonged 
SKBF. 
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Figure 7.8 The effect of incremental and prolonged heating on SKBF in the saline and 
L-NMMA microdialysis sites pre (A) and post conventional care (B) *Significant 
difference between L-NMMA and saline sites (P<0.05). 0 min-peak SKBF, 30 min-
prolonged SKBF. 
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Figure 7.9 The effect of exercise and conventional care on the NO contribution (saline 
%CVCmax minus L-NMMA %CVCmax) to SKBF in response to incremental heating. 
*Significant difference between pre and post exercise (P<0.05). 0 min-peak SKBF, 30 
min-prolonged SKBF. 
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7.3.7 Δ Change in response to incremental heating 
There was no significant interaction between exercise and convention care in the saline 
or L-NMMA microdialysis sites (P>0.13). Nevertheless, a significant interaction was 
evident for NO contribution (P=0.01). Pairwise comparisons revealed that the exercise 
group demonstrated a significantly greater NO response to incremental heating from 
37.5°C (11.0 %CVCmax) to 42°C (33.6 %CVCmax; P<0.05; Figure 7.10). 
 
 
 
 
Figure 7.10 The change in the contribution of NO (saline %CVCmax minus L-NMMA 
%CVCmax) to SKBF in response to incremental heating following the exercise and 
conventional care intervention. *Significant difference between exercise and 
conventional care (P<0.05). 0 min-peak SKBF, 30 min-prolonged SKBF. 
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The contribution of NO to SKBF at rest (3.3±2.5 vs. -5.8±2.7 %CVCmax; P=0.04; 
Figure 7.11) and at peak heating (42°C) (22.5±9.7 vs. -18.0±8.1 %CVCmax; P=0.05; 
Figure 7.11) was significantly greater following exercise-training when compared with 
conventional care. There were no significant differences between groups in the 
contribution of NO to SKBF following prolonged heating at 42°C (Figure 7.11). 
 
.  
 
Figure 7.11 The change in mean NO contribution to resting, peak (42°C) and prolonged 
(30 mins at 42°C) SKBF in the NAFLD patients following the exercise and 
conventional care intervention.  
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7.4 Discussion 
The aim of this study was to investigate cutaneous microvascular function in NAFLD 
patients. The major findings were that (i) cutaneous NO-mediated microvascular 
function was similar in NAFLD when compared with age, BMI and fitness matched 
controls; and (ii) supervised exercise training induced an increase in NO contribution, 
indicative of greater NO bioavailability, during incremental heating when compared 
with conventional care. These findings suggest, for the first time that supervised 
exercise training is an effective management strategy capable of improving NO-
mediated cutaneous microvascular function in NAFLD patients. 
 
This is the only study to explore cutaneous microvessel function in NAFLD. The 
current results report no differences in the cutaneous microvasculature between NAFLD 
patients (prior to randomised intervention) and matched control individuals. A likely 
explanation for this is that NAFLD patients were compared with sedentary and obese 
controls. Previous studies have suggested that cutaneous microvessel dysfunction in 
healthy individuals is explained by age (Black et al., 2008b) and/or fitness (Black et al., 
2008b). Similarly, obesity has also been shown to impair cutaneous microvessel 
function in healthy individuals (de Jongh et al., 2004). Therefore, as NAFLD and 
controls were obese sedentary individuals, it is plausible that microvascular dysfunction 
was present in both NAFLD and controls due to similar lifestyle practice. This finding 
is corroborated by Sokolnicki et al. (2007) who reported no difference in the relative 
contribution of NO to SKBF during local heating between type 2 diabetics (a patient 
group that shares the common pathology of insulin resistance) and matched controls. 
 
Previous research suggests that exercise training is an effective treatment strategy to 
improve cutaneous microvessel function in young (Wang, 2005) and older sedentary 
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individuals (Black et al., 2008) as well as postmenopausal women (Hodges et al., 2010). 
The current study utilised a randomised control intervention, whereby NAFLD patients 
either underwent a supervised moderate intensity exercise training program or a 
conventional care intervention which adhered to the current clinical treatment 
guidelines for patients diagnosed with NAFLD (weight loss and increased physical 
activity). The supervised exercise intervention mediated a greater NO response to the 
incremental heating protocol than conventional care. Specifically, the exercise 
intervention mediated an up-regulation of NO during heating, characterised by a greater 
contribution of NO and subsequent increase in SKBF; which were only apparent as 
temperature increased above 37.5°C. This finding of increased NO contribution with 
exercise training corroborates previous data in sedentary elderly individuals (Black et 
al., 2008b) and suggests that up-regulation of NO in response to incremental local 
heating in the microvasculature may be a function of enhanced cardiorespiratory fitness. 
Furthermore, the NO contribution to SKBF at rest was greater following supervised 
exercise training when compared with conventional care. To our knowledge this also is 
a novel finding, which indicates exercise training may increase the tonic release of NO 
and thus promote an improved basal microvascular function. In the current study, 
improved NO-mediated microvascular function was associated with enhanced 
endurance capacity, a finding consistent with that of Black et al. (2008b).  The 
importance of changes in fitness status are also evidenced by the observation that no 
changes were found in microvascular function following 6-months of aerobic exercise 
training in type 2 diabetic patients that exhibited no improvement in cardiorespiratory 
fitness (Middlebrooke et al., 2006). 
 
Whilst the current data suggest that exercise training up-regulates the NO contribution 
to local heating, peak vasodilator capacity remains similar following the different 
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treatment regimes. Following conventional care, peak vasodilator capacity was 
maintained despite an apparent reduction in the contribution of NO. Therefore, it is 
likely that compensatory vasodilator mechanisms (such as prostacyclins) exist which 
preserve heat-induced vasodilator responses in the presence of impaired NO-mediated 
microvascular function. In contrast, exercise training increased NO bioavailability 
which may modulate the balance between NO and alternative vasodilatory pathways, 
causing compensatory vasodilator mechanisms to become redundant. Indeed, the 
presence of redundancy in vasomotor control is well recognised in other arterial beds 
(Joyner & Wilkins, 2007). 
 
Direct therapeutic effects of exercise on the cutaneous microvasculature are evidenced 
by the present study, via improvements in NO-mediated cutaneous microvessel function 
following exercise training occurring without reductions in weight, IHTC or abdominal 
VAT. Moreover, as predominantly lower limb exercise training induced an 
enhancement in cutaneous microvessel NO vasodilator function in the forearm, these 
data suggest that exercise training has a systemic therapeutic effect on cutaneous 
microvascular function. This finding is corroborated by Black et al. (2008b) who 
reported a similar systemic impact of exercise on cutaneous microvascular function in 
old sedentary healthy individuals. 
 
There are a number of noteworthy methodological issues concerning this study which 
warrant consideration. An advantage of the current study is the utilisation of intradermal 
microdialysis as the optimal technique (Cracowski et al., 2006) to elicit NO blockade 
allowing specific evaluation of NO contribution to cutaneous microvessels during 
incremental heating. Previous training studies have demonstrated that exercise improves 
acetylcholine-mediated vasodilatation, which infers an increase in NO production. 
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Whilst acetylcholine is a precursor of vasodilatation, it is not exclusive to NO, as it only 
accounts for ~30-60% of the NO-mediated vasodilator response (Kellogg et al., 2005). 
Furthermore, these studies utilised the iontophoresis approach, which has well accepted 
limitations (Cracowski et al., 2006). Intradermal microdialysis facilitates the infusion of 
a potent NO blockade enabling the exclusive evaluation of NO contribution to 
cutaneous microvessel vasodilator responses. One possible limitation of this study is 
that, unlike previous intradermal microdialysis studies which infused N-nitro-L-arginine 
methyl ester (L-NAME) to elicit NO blockade during incremental heating (Kellogg et 
al., 1999; Black et al., 2008b), the current study utilised a less potent NO blocker, L-
NMMA.  Although L-NMMA is a less potent NO blocker than L-NAME (Goldsmith et 
al., 1996), it has been reported to elicit similar specific inhibitory effects on NO-
mediated vasodilatation (Dietz et al., 1994). 
 
In summary, the findings from this study suggest that cutaneous microvascular function 
can be improved in NAFLD patients; via an up regulation of the anti-atherogenic 
molecule NO. Furthermore, the therapeutic effects of supervised exercise training are 
superior to that of current conventional care guidelines and infer a reduction in CVD 
risk independent of weight loss and diminished IHTC and abdominal VAT.  
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Chapter 8 
SYNTHESIS OF FINDINGS 
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8.1 Aims and Objectives 
The research work undertaken in this thesis was designed to investigate cardiovascular 
and metabolic health in non-alcoholic fatty liver disease (NAFLD) and to establish 
whether supervised exercise training could ameliorate the cardio-metabolic status of 
NAFLD patients. Specifically, the studies described in this thesis investigated the 
impact of intrahepatocellular triglyceride content (IHTC) and abdominal visceral 
adipose tissue (VAT) on conduit artery endothelial function and, for the first time, 
examined cutaneous microvessel endothelial function in NAFLD patients. Additionally, 
a major focus of this thesis was to investigate whether a 16-week supervised exercise 
training program of moderate intensity had a therapeutic impact on conduit artery and 
cutaneous microvessel endothelial function that exceeded the effect of the current 
conventional care guidelines in the UK. Finally, a 12-month follow up assessment was 
performed after the cessation of supervised exercise training in an attempt to explore the 
longevity of any exercise-induced improvements in conduit artery endothelial function 
and IHTC in NAFLD.  
 
8.2 General Discussion  
CVD is the leading cause of mortality in NAFLD patients, exceeding that of liver 
disease (Ekstedt et al., 2006; Ong et al., 2008). Endothelial dysfunction is an early 
marker in the development of atherosclerosis and predictor of future cardiovascular 
events, and therefore was the primary outcome variable within this thesis. Previous 
research has demonstrated that brachial artery FMD is impaired in NAFLD patients 
when compared with age (Villanova et al., 2005; Senturk et al., 2008) and overweight 
(Vlachopoulos et al., 2010) matched controls. Insulin resistance is a key pathological 
feature of NAFLD and has been associated with impaired FMD in these patients 
(Villanova et al., 2005).  Importantly, there is a strong association between insulin 
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resistance, abdominal VAT and hepatic steatosis in NAFLD (Chitturi et al., 2002; Park 
et al., 2007). Notably, VAT is positively correlated with steatosis (Kelley et al., 2003; 
Nguyen-Duy et al., 2003) independently of insulin resistance (van der Poorten et al., 
2008) and has been found to be a predictor of CVD (Despres, 2007; Petta et al., 2009). 
Specifically, VAT has been reported to be a determinant of endothelial dysfunction, 
independent of traditional risk factors, in morbidly obese individuals (Sturm et al., 
2009). Taken together, these data indicate that VAT is a pivotal feature in the 
pathogenesis of NAFLD, which may infer additional risk of future cardiovascular 
events. Nevertheless, no previous research has quantified IHTC and abdominal VAT in 
NAFLD in order to examine the impact of these fat depots on endothelial function. 
 
Chapter 4 confirmed that obese NAFLD patients exhibit impaired FMD when compared 
with age and BMI matched controls, and thus express a reduced production of the anti-
atherogenic molecule, NO, in response to increases in blood flow and associated shear 
stress. However, when co-varied, the impairment in endothelial function was not 
explained by IHTC or abdominal VAT. Following 16-weeks of supervised moderate 
intensity exercise training brachial artery endothelial function in NAFLD patients 
improved (Chapter 5). Importantly, supervised exercise training induced a significantly 
greater improvement in endothelial function than current conventional care guidelines. 
Chapter 6 demonstrated that exercise-induced improvements in endothelial function 
were abolished 12-months following the cessation of supervised exercise. Chapter 7 
illustrated that cutaneous NO-mediated microvascular function was not impaired in 
NAFLD when compared with age, BMI and cardiorespiratory fitness matched controls. 
Nevertheless, supervised exercise training enhanced NO contribution to skin blood flow 
(SKBF) in the microvessels of NAFLD patients to a greater degree than that of 
conventional care. 
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Flow mediated dilatation (FMD) is an early clinical marker of CVD, which was found 
to be impaired in NAFLD when compared with matched controls, indicative of 
diminished NO bioavailability and subsequent endothelial dysfunction. Previous 
research has reported that FMD is an independent predictor of future cardiovascular 
events in high risk individuals, whereby risk of an event is approximately nine-fold 
higher in individuals with a FMD response below 8.1% (Gokce et al., 2003). Chapter 4 
demonstrated that despite being obese and sedentary, characteristics known to 
independently predict endothelial dysfunction (Black et al., 2009; Davison et al., 2010) 
the control participants elicited a relatively healthy FMD response (8.3±0.7%), 
compared with NAFLD (4.3±0.3%). These data indicate that NAFLD may provoke a 
detrimental impact on conduit artery endothelial function, which exceeds the adverse 
effects of global obesity and sedentary behaviour (Figure 8.1), and exposes these 
patients to significantly heightened risk of CVD.  
 
In contrast to the observed impairment in conduit artery endothelial function, no 
differences were seen in cutaneous vasodilator function between NAFLD and matched 
controls at baseline, which may infer that NO-mediated cutaneous microvascular 
function is not impaired in NAFLD. However, when compared with the findings of 
Black et al. (2008b), who reported that the NO contribution to SKBF in response to 
peak heating was ~40% in young sedentary individuals and ~50% in older fit 
individuals, the data presented in Chapter 7 indicates that both NAFLD and controls 
demonstrated impaired cutaneous endothelial function, as both groups only elicit a ~30% 
NO contribution in response to the same peak heating stimulus. This finding is 
corroborated by Sokolnicki et al., (2007) who reported a similar NO contribution to 
SKBF during peak body heating (~30%) in overweight type 2 diabetics and BMI 
matched control individuals. These data suggest that NO-mediated cutaneous 
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microvascular function may be more susceptible to the adverse impact of obesity and 
sedentary behaviour than conduit arteries. Indeed as depicted in Figure 8.1, it is 
plausible that microvascular dysfunction precedes any dysfunction found in the larger 
conduit arteries, implying that the cutaneous microcirculation could be used as a marker 
to investigate endothelial dysfunction at an early stage in the care pathways of patients. 
Despite this observation, the findings of this thesis indicate that NAFLD provokes an 
additional detrimental impact on conduit artery endothelial function, over and above 
that caused by lifestyle factors (Figure 8.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 A schematic illustrating that as the severity of NAFLD and its associated 
comorbidities increases, vascular dysfunction becomes more aggressive. 
   
As cutaneous NO-mediated  microvessel function reflects generalised microvascular 
function and provides a translational model to investigate pre-clinical disease  
(Holowatz et al., 2008), the deficit described in Chapter 7 supports the previous 
research that suggests hepatic microvessel function is impaired in NAFLD (Ijaz et al., 
2003). However, this raises the question of whether NAFLD directly provokes 
microvessel dysfunction, or whether generalised microvascular dysfunction precedes 
NAFLD and impacts on hepatic metabolism, which subsequently promotes triglyceride 
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accumulation within the hepatocytes. Indeed, this is a research area that warrants further 
investigation in the future. 
 
Chapters 5 and 7 indicate that there is no statistical difference between the therapeutic 
impact of supervised exercise training and conventional care on IHTC. Nevertheless, 
these Chapters did demonstrate that supervised exercise training induced clinically 
relevant absolute reductions (9-13%) in IHTC in NAFLD patients which are 
comparable with previous findings (Bonekamp et al., 2008; Johnson et al., 2009; van 
der Heijden et al., 2010). In contrast, supervised moderate intensity exercise did not 
induce a reduction in abdominal VAT. A previous study observed a 12% relative 
reduction in abdominal VAT in NAFLD patients following four weeks of high intensity 
cycle ergometer exercise training (Johnson et al., 2009). Therefore, it is plausible that a 
higher intensity exercise training intervention may have mediated a reduction in 
abdominal VAT. 
 
Supervised exercise training induced a clinically significant reduction in IHTC, 
enhanced cardiorespiratory fitness and improved endothelial function across different 
levels of the vascular tree in sedentary and obese NAFLD patients. The exercise-
induced improvement in FMD and NO contribution to SKBF in cutaneous microvessels 
compare with other diseased or aging populations (Maiorana et al., 2000; Maiorana et 
al., 2001; Black et al., 2008b). It is interesting to note that the exercise-induced 
improvement in FMD relative to baseline was 73%, whereas a 100% improvement was 
observed in the NO contribution to peak cutaneous microvessel blood flow. Although 
these improvements are broadly similar, these data suggest that NO-mediated cutaneous 
microvessel function is more amenable to exercise-mediated enhancement than conduit 
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arteries in NAFLD, again implying that the microcirculation is more plastic and 
susceptible to change. 
 
The results in Chapters 5 and 7 imply that the exercise-induced improvement in 
endothelial function was due to an increase in NO production, rather than an increase in 
sensitivity of the smooth muscles cells. Regular exercise training promotes an increase 
in NO bioavailability by reducing the number of oxygen free radicals and up-regulating 
endothelial NO synthase protein (Green et al., 2004a; Green et al., 2008). Increased NO 
bioavailability is thought to be caused by recurrent increases in shear stress as a result 
of repeated exercise bouts (Green et al., 2010). The chronic enhancements observed in 
NAFLD patients are indicative of an increase in NO production, which promotes 
efficient vasomotor function and decreases the risk of atherosclerotic development. 
Critically, previous evidence demonstrates that interventions which improve NO 
dependent endothelial function are associated with improved mortality and morbidity in 
similar diseased populations (O'Driscoll et al., 1997; O'Driscoll et al., 1999). This is of 
vital clinical importance given that CVD is the leading cause of mortality in NAFLD 
(Ong et al., 2008). 
 
Enhanced FMD and cutaneous microvessel function was evident independent of 
statistically significant reductions in IHTC and abdominal VAT. These findings suggest 
that exercise has an independent and direct therapeutic impact on both conduit artery 
and cutaneous microvessel endothelial function in these patients who are at high risk of 
CVD and future cardiovascular events. Moreover, since lower limb exercise training 
induced the enhancements seen in both conduit artery and cutaneous microvessel NO 
vasodilator function of the upper limb, these data suggest that exercise training has a 
systemic therapeutic effect on endothelial function across the vasculature in NAFLD. 
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This finding is corroborated by Black and colleagues (2009), who reported that lower 
limb exercise had a similar systemic impact on conduit artery and cutaneous 
microvascular function of the upper limb, in old sedentary individuals. 
 
A noteworthy observation of this thesis and a powerful public health message is that 
moderate intensity exercise training is capable of improving conduit artery and 
cutaneous microvessel endothelial function in NAFLD. It would be interesting to 
investigate whether exercise training of a higher intensity induced any additional 
benefits to cardiovascular and metabolic health in NAFLD, particularly given the 
observation that high intensity training reduces abdominal VAT by 12% (Johnson et al., 
2009) in these patients. However, given that Chapter 6 demonstrated that the cardio-
protective impact of supervised moderate intensity exercise training was abolished by 
patients returning to sedentary habits, 12-months following the cessation of supervision; 
it is unlikely that long term compliance to high intensity exercise training would be 
maintained. 
 
8.3 Methodological considerations and limitations 
This thesis has several noteworthy advantages in terms of methodology. Firstly, the use 
of whole body magnetic resonance imaging (MRI) to quantify fat deposition and the 
non-invasive gold standard proton magnetic resonance spectroscopy (1H-MRS) allowed 
very precise quantification of hepatic fat in all of the studies. Secondly, utilisation of the 
most recent peer reviewed guidelines and technology to assess FMD (Thijssen et al., 
2011) coupled with the utilisation of custom designed edge detection and wall tracking 
analysis software, brought maximal precision to these measurements. Thirdly, 
employment of a randomised control trial in Chapters 5 and 7 minimised allocation bias 
in the assignment of care pathways. Finally, use of intradermal microdialysis allowed 
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the interrogation of the control mechanisms of the microcirculation by using both 
agonist and antagonist vasoactive substances to challenge cutaneous NO-mediated 
microvascular function. 
 
Despite these advantages, the studies within this thesis have a number of limitations. 
Although rigorous inclusion and exclusion criteria and in-depth diagnosis were 
employed, participants did not undergo a liver biopsy to histologically confirm the 
diagnosis of NAFLD. Consequently, it was not possible to stratify between simple 
steatosis and NASH. Furthermore, a measurement of peripheral insulin resistance was 
not incorporated within the thesis and is clearly an area for future study, since this 
would have provided a powerful covariate to the analysis.  
 
8.4 Future Directions 
There are several potential areas of future research which have emerged from the data 
presented in this thesis. Primarily, further examination of the relationship between, 
insulin resistance and endothelial dysfunction in NAFLD patients is warranted. 
Specifically, future studies should employ the euglycaemic clamp technique as a more 
robust measure of peripheral insulin resistance. Moreover, as isolated hallmark features 
of NAFLD such as IHTC, abdominal VAT and insulin resistance do not totally explain 
the decrement in FMD, investigation into the relationship between endothelial 
dysfunction and other less overt pathological features, such as the excess secretion of 
inflammatory cytokines, including TNF-α and leptin may be warranted.  
 
Although no difference in cutaneous NO-mediated microvascular function was 
observed in NAFLD when compared with age, BMI and cardiorespiratory fitness 
matched controls, future research should compare microvessel endothelial function of 
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NAFLD patients with lean controls, sub-divided by cardiorespiratory fitness, in order to 
further interrogate the impact of obesity and sedentary behaviour on cutaneous NO-
mediated microvascular function. Furthermore, as the peak vasodilator capacity of 
cutaneous microvessels was maintained following conventional care despite an apparent 
reduction in the contribution of NO, future studies should investigate other 
compensatory vasodilator mechanisms (such as prostacyclins) that may exist to preserve 
heat-induced vasodilator responses in the presence of diminished microvascular NO 
bioavailability.  
 
Future research investigating the impact of exercise training on endothelial function in 
biopsy-proven NASH patients would be of great clinical relevance. Villanova et al. 
(2005) illustrated that NASH patients exhibit more pronounced endothelial impairment 
than patients with isolated simple steatosis.  However, it is currently unknown whether 
exercise training has a similar therapeutic impact on endothelial function as the severity 
and scale of NAFLD worsens. Similarly, the therapeutic impact of high intensity 
exercise on fat deposition and endothelial function warrants further consideration.  
Finally, in order to further evaluate the longevity of supervised exercise training, future 
follow up studies should provide intermittent guidance counselling (perhaps using 
mobile technologies) throughout the cessation period to establish whether minimal 
communication can aid the chronic sustainability of exercise-induced improvements to 
cardiovascular health in NAFLD. 
 
8.5 Summary and Conclusions 
The primary aim of this thesis was to explore NO-mediated endothelial function at 
different levels of the vascular tree in NAFLD patients and to establish whether 
supervised exercise training had a sustained therapeutic impact on endothelial function. 
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The findings of this thesis provide novel data for the literature, and significantly 
advance our understanding of endothelial function in NAFLD patients and the 
cardioprotective role of supervised exercise training in this high risk group. 
  
The findings of this thesis indicate that NO-mediated endothelial dysfunction is present 
in the brachial artery of NAFLD patients. Moreover, impaired conduit artery endothelial 
function in NAFLD is not explained by elevated IHTC or abdominal VAT. Supervised 
exercise training improved brachial artery and cutaneous microvessel NO-mediated 
endothelial function in sedentary and obese NAFLD patients. Improvements in 
endothelial function at different levels of the vascular tree occurred without statistically 
significant reductions in IHTC or abdominal VAT. However, the improvement 
observed in brachial artery NO-mediated endothelial function was abolished 12-months 
following the cessation of supervised exercise training.  
 
8.6 Clinical Relevance and Recommendations  
The research work undertaken in this thesis supports previous evidence indicating that 
NAFLD, per se, infers an adverse CVD risk profile, but importantly, also provides 
information pertaining to the extent of CVD risk evident in this clinical population. 
Recently published robust risk ratios indicate that the risk of a cardiovascular event 
increases by 21% for every 1 standard deviation (=3.5%) decrease in FMD (Inaba et al., 
2010). Chapter 4 demonstrated a mean reduction in FMD of 3.5% in NAFLD patients 
compared with control participants, inferring that NAFLD patients are 21% more likely 
to experience a cardiovascular event than individuals without NAFLD who are of a 
similar age, fitness and BMI. Additionally, chapters 5 and 6 are the first studies to 
demonstrate the therapeutic effects of supervised exercise training on conduit artery and 
cutaneous microvessel health in NAFLD patients. Indeed, supervised exercise training 
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mediated a mean improvement in FMD of 3.6% in NAFLD patients, which according to 
the prognostic data published by Inaba and colleagues (2010) may have reduced the risk 
of a cardiovascular event by ~21% in this high risk group.  Given that CVD is the 
leading cause of death in NAFLD patients, exceeding that of liver related mortality 
(Ekstedt et al., 2006; Ong et al., 2008), the findings of this thesis have the potential to 
impact clinical practice and subsequently improve the CVD related prognosis of this 
high risk group. 
 
The findings of this thesis indicate that the therapeutic effects of supervised exercise 
training are superior to that of current conventional care guidelines and confer a 
reduction in CVD risk independent of weight loss and diminished IHTC and abdominal 
VAT. Consequently, these data indicate that exercise has an independent and direct 
therapeutic impact on endothelial function in NAFLD, which may decrease the risk of 
heart disease and stroke in these high risk patients. Nevertheless, in order to chronically 
sustain exercise-induced improvements in the endothelial function, long term exercise 
supervision and guidance is required. Since higher levels of NO confer anti-atherogenic 
benefit, the findings of this thesis have potentially important implications for the 
prevention of macro and micro-vascular dysfunction in NAFLD and imply that 
supervised exercise prescription should be recommended as a cardioprotective 
management strategy. 
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